1
|
Williams IA, Morris PG, Forristal K, Stone J, Gillespie DC. Illness representations of people with later-onset functional seizures. Epilepsy Behav 2024; 152:109666. [PMID: 38382188 DOI: 10.1016/j.yebeh.2024.109666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/23/2024]
Abstract
PURPOSE Although functional seizures can start at any age, little is known about the individuals for whom onset occurs after the age of 40. It has been proposed that health-related traumatic events are more relevant causal factors for people with 'later-onset functional seizures' than for those whose functional seizures begin earlier in life, however, the illness representations of people with later-onset functional seizures have not yet been investigated. This study aimed to understand the experiences and illness representations of people with later-onset functional seizures. METHODS This was a mixed-methods study. People with later-onset functional seizures were recruited via a neurologist's caseload and online membership-led organisations. Semi-structured interview transcripts were analysed using Template Analysis according to the Common-Sense Model (CSM). Self-report measures of demographic and clinical details were collected to characterise the sample and verify themes. RESULTS Eight people with later-onset functional seizures participated in the study. Illness representations relating to all domains of the CSM as well as an additional theme of 'Triggers' were identified. Functional seizures were characterised as a mysterious brain disorder analogous to a computer malfunction and involving involuntary movements associated with alterations in consciousness. Perceptions of duration were indefinite, and triggers were unknown or at the extremes of autonomic arousal. Half of the sample identified health-related events/trauma as causal. Opinions were divided on 'cumulative life stress' as a causal factor. Most perceived themselves to have limited or no control but having 'control' over seizures was conceptualised as different to reducing their likelihood, frequency, or impact. Later-onset functional seizures were viewed as being more detrimental for caring and financial responsibilities but to have advantages for acceptance. CONCLUSIONS This is the first study to assess the illness representations of people with later-onset functional seizures. Many themes were similar to those identified in samples including people with earlier-onset functional seizures. Health-related trauma or events were the most strongly endorsed perceived causal factor, but with the exception of 'consequences', all representations were characterised by uncertainty. Clinicians should hold in mind the interaction between life stage and the consequences of later-onset functional seizures.
Collapse
Affiliation(s)
- I A Williams
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK; Department of Clinical and Health Psychology, The University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK.
| | - P G Morris
- Department of Clinical and Health Psychology, The University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK
| | - K Forristal
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
| | - J Stone
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
| | - D C Gillespie
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, UK
| |
Collapse
|
2
|
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT. The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer. Breast Cancer Res Treat 2021; 187:635-645. [PMID: 33983492 PMCID: PMC8197702 DOI: 10.1007/s10549-021-06244-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Accepted: 04/22/2021] [Indexed: 11/28/2022]
Abstract
Background Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels with subsequent pCR, few have studied the impact of neoadjuvant therapy on the immune environment. Methods We performed TIL analysis and T-cell analysis by IHC on the pretreatment and ‘On-treatment’ samples from patients recruited on the Phase-II TCHL (NCT01485926) clinical trial. Data were analysed using the Wilcoxon signed-rank test and the Spearman rank correlation. Results In our sample cohort (n = 66), patients who achieved a pCR at surgery, post-chemotherapy, had significantly higher counts of TILs (p = 0.05) but not SLs (p = 0.08) in their pre-treatment tumour samples. Patients who achieved a subsequent pCR after completing neo-adjuvant chemotherapy had significantly higher SLs (p = 9.09 × 10–3) but not TILs (p = 0.1) in their ‘On-treatment’ tumour biopsies. In a small cohort of samples (n = 16), infiltrating lymphocyte counts increased after 1 cycle of neo-adjuvant chemotherapy only in those tumours of patients who did not achieve a subsequent pCR. Finally, reduced CD3 + (p = 0.04, rho = 0.60) and CD4 + (p = 0.01, rho = 0.72) T-cell counts in 'On-treatment' biopsies were associated with decreased residual tumour content post-1 cycle of treatment; the latter being significantly associated with increased likelihood of subsequent pCR (p < 0.01). Conclusions The immune system may be ‘primed’ prior to neoadjuvant treatment in those patients who subsequently achieve a pCR. In those patients who achieve a pCR, their immune response may return to baseline after only 1 cycle of treatment. However, in those who did not achieve a pCR, neo-adjuvant treatment may stimulate lymphocyte influx into the tumour. Supplementary Information The online version contains supplementary material available at 10.1007/s10549-021-06244-1.
Collapse
Affiliation(s)
- A J Eustace
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
| | - S F Madden
- Data Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - J Fay
- Department of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - D M Collins
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - E W Kay
- Department of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - K M Sheehan
- Department of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland.,Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - S Furney
- Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - B Moran
- Conway Institute, University College Dublin, Dublin, Ireland
| | - A Fagan
- Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - P G Morris
- Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
| | | | - A D Hill
- Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - L Grogan
- Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
| | - J M Walshe
- Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland
| | - O Breathnach
- Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
| | - C Power
- Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - D Duke
- Department of Radiology, Beaumont Hospital, Dublin, Ireland
| | - K Egan
- Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland
| | - W M Gallagher
- Conway Institute, University College Dublin, Dublin, Ireland
| | - N O'Donovan
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
| | - J Crown
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.,Cancer Trials Ireland, Dublin, Ireland
| | - S Toomey
- Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - B T Hennessy
- Cancer Trials Ireland, Dublin, Ireland.,Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| |
Collapse
|
3
|
Keogh RJ, Milewski M, Browne K, Egan K, Hennessy MA, Coyne Z, Cowzer D, Linehan A, Hennessy BT, Grogan L, Morris PG, Breathnach OS. An exploration of the impact of ethanol diluent on breath alcohol concentration in patients receiving paclitaxel chemotherapy. Cancer Chemother Pharmacol 2021; 88:307-312. [PMID: 33944970 DOI: 10.1007/s00280-021-04279-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 04/14/2021] [Indexed: 11/30/2022]
Abstract
PURPOSE This study aimed to provide a better understanding of the impact of paclitaxel chemotherapy on breath alcohol in an Irish population. METHODS Patients attending the Oncology Day Unit at Beaumont Hospital were invited to participate on the day of their treatment. The brand of paclitaxel used was Actavis Pharma Inc and contained 6 mg/mL paclitaxel in 50% Ethanol/ 50% Cremophor EL. Breath alcohol concentration was measured using the AlcoSense ™ Breathalyser on three separate visits. The primary end-point was the number of patients who were above the legal threshold for drink driving in Ireland. RESULTS In total, 50 patients were recruited. 36 (68%) were female. The most common diagnosis was breast cancer (56%). Ten (20%) patients had metastatic disease and 4 (8%) had liver metastases. The mean paclitaxel dose administered was 118 mg. The mean amount of ethanol infused was 7.7 g. 27 patients had a detectable breath alcohol level on at least one visit. The mean breath alcohol concentration was 2 mcg/100 mL or 0.02 mg/L of breath. The maximum concentration of ethanol in exhaled breath was 11 mcg/100 mL or 0.11 mg/L which is 50% of the statutory limit for drink driving in Ireland. A weak correlation was observed between ethanol concentration in exhaled breath and the total amount of ethanol administered. Although no patient exceeded the general limit for drink driving in Ireland, three (6%) participants had a breath alcohol concentration above the threshold for professional, learner or novice drivers. CONCLUSION Although definitive conclusions are limited by relatively small numbers, it seems unlikely that weekly paclitaxel infusions pose any significant risk to patients driving.
Collapse
Affiliation(s)
- R J Keogh
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
| | - M Milewski
- Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland
| | - K Browne
- Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland
| | - K Egan
- Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland
| | - M A Hennessy
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland
| | - Z Coyne
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland
| | - D Cowzer
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland
| | | | - B T Hennessy
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.,Royal College of Surgeons Ireland, Dublin, Ireland
| | - L Grogan
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland
| | - P G Morris
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.,Royal College of Surgeons Ireland, Dublin, Ireland
| | - O S Breathnach
- Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.,Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin 9, Ireland.,Royal College of Surgeons Ireland, Dublin, Ireland
| |
Collapse
|
4
|
Fernandes CC, Lanz B, Chen C, Morris PG, Salmon CG. Investigating the regional effect of the chemical shift displacement artefact on the J-modulated lactate signal at ultra high-field. NMR Biomed 2021; 34:e4440. [PMID: 33140530 DOI: 10.1002/nbm.4440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Revised: 10/06/2020] [Accepted: 10/13/2020] [Indexed: 06/11/2023]
Abstract
The present work aims to show the applicability of an analytical model for the optimisation of the STEAM sequence timing parameters for lactate detection at ultra high-field. The effects of the chemical shift displacement artefact on the J-modulated signal for a weakly-coupled spin system were considered in the three applied directions of field gradients and the product operator formalism was used to obtain expressions for the signal modulation in each compartment of the excited volume. The validity of this model was demonstrated experimentally at 7 T in a phantom and acquisitions with optimised parameters were performed on a healthy volunteer. The spectra acquired with TE = 144 ms with the optimised mixing time and TE = 288 ms showed easily detectable lactate peaks in the normal human brain. Additionally, the acquisition with the longer TE resulted in a spectrum with less lipid/macromolecular contamination. The simulations shown here demonstrated that the proposed analytical model is suitable for correctly predicting the resulting lactate signal. With the optimised parameters, it was possible to use a simple sequence with sufficient signal-to-noise ratio to reliably distinguish lactate from overlapping resonances in a healthy brain.
Collapse
Affiliation(s)
- Carolina C Fernandes
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
| | - Bernard Lanz
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
| | - Chen Chen
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
| | - Carlos G Salmon
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
- Department of Physics, University of Sao Paulo, Riberao Preto, Sao Paulo, Brazil
| |
Collapse
|
5
|
Gascoyne LE, Brookes MJ, Rathnaiah M, Katshu MZUH, Koelewijn L, Williams G, Kumar J, Walters JTR, Seedat ZA, Palaniyappan L, Deakin JFW, Singh KD, Liddle PF, Morris PG. Motor-related oscillatory activity in schizophrenia according to phase of illness and clinical symptom severity. Neuroimage Clin 2020; 29:102524. [PMID: 33340975 PMCID: PMC7750164 DOI: 10.1016/j.nicl.2020.102524] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 11/12/2020] [Accepted: 12/01/2020] [Indexed: 11/19/2022]
Abstract
Magnetoencephalography (MEG) measures magnetic fields generated by synchronised neural current flow and provides direct inference on brain electrophysiology and connectivity, with high spatial and temporal resolution. The movement-related beta decrease (MRBD) and the post-movement beta rebound (PMBR) are well-characterised effects in magnetoencephalography (MEG), with the latter having been shown to relate to long-range network integrity. Our previous work has shown that the PMBR is diminished (relative to controls) in a group of schizophrenia patients. However, little is known about how this effect might differ in patients at different stages of illness and degrees of clinical severity. Here, we extend our previous findings showing that the MEG derived PMBR abnormality in schizophrenia exists in 29 recent-onset and 35 established cases (i.e., chronic patients), compared to 42 control cases. In established cases, PMBR is negatively correlated with severity of disorganization symptoms. Further, using a hidden Markov model analysis, we show that transient pan-spectral oscillatory "bursts", which underlie the PMBR, differ between healthy controls and patients. Results corroborate that PMBR is associated with disorganization of mental activity in schizophrenia.
Collapse
Affiliation(s)
- Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Mohanbabu Rathnaiah
- Institute of Mental Health, University of Nottingham, Jubilee Campus, Nottingham NG7 2TU, United Kingdom; Nottinghamshire Healthcare NHS Foundation Trust, Nottingham NG3 6AA, United Kingdom
| | - Mohammad Zia Ul Haq Katshu
- Institute of Mental Health, University of Nottingham, Jubilee Campus, Nottingham NG7 2TU, United Kingdom; Nottinghamshire Healthcare NHS Foundation Trust, Nottingham NG3 6AA, United Kingdom
| | - Loes Koelewijn
- CUBRIC, School of Psychology, College of Biomedical and Life Sciences, Cardiff, Cardiff University CF24 4HQ, United Kingdom
| | - Gemma Williams
- CUBRIC, School of Psychology, College of Biomedical and Life Sciences, Cardiff, Cardiff University CF24 4HQ, United Kingdom
| | - Jyothika Kumar
- Institute of Mental Health, University of Nottingham, Jubilee Campus, Nottingham NG7 2TU, United Kingdom
| | - James T R Walters
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, CF24 4HQ, United Kingdom
| | - Zelekha A Seedat
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Lena Palaniyappan
- Department of Psychiatry & Robarts Research Institute, University of Western Ontario & Lawson Health Research Institute, London ON, Canada
| | - J F William Deakin
- Division of Neuroscience and Experimental Psychology, University of Manchester, Oxford Rd, Manchester M13 9PL, United Kingdom
| | - Krish D Singh
- CUBRIC, School of Psychology, College of Biomedical and Life Sciences, Cardiff, Cardiff University CF24 4HQ, United Kingdom
| | - Peter F Liddle
- Institute of Mental Health, University of Nottingham, Jubilee Campus, Nottingham NG7 2TU, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| |
Collapse
|
6
|
Carradus AJ, Mougin O, Hunt BAE, Tewarie PK, Geades N, Morris PG, Brookes MJ, Gowland PA, Madan CR. Age-related differences in myeloarchitecture measured at 7 T. Neurobiol Aging 2020; 96:246-254. [PMID: 33049517 DOI: 10.1016/j.neurobiolaging.2020.08.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 08/06/2020] [Accepted: 08/10/2020] [Indexed: 01/01/2023]
Abstract
We have used the magnetisation transfer (MT) MRI measure as a primary measure of myelination in both the gray matter (GM) of the 78 cortical automated anatomical labeling (AAL) regions of the brain, and the underlying white matter in each region, in a cohort of healthy adults (aged 19-62 year old). The results revealed a significant quadratic trend in myelination with age, with average global myelination peaking at 42.9 year old in gray matter, and at 41.7 year old in white matter. We also explored the possibility of using the Nuclear Overhauser Enhancement (NOE) effect, which is acquired in a similar method to MT, as an additional measure of myelination. We found that the MT and NOE signals were strongly correlated in the brain and that the NOE effects displayed similar (albeit weaker) parabolic trends with age. We also investigated differences in cortical thickness with age, and confirmed a previous result of a linear decline of 4.5 ± 1.2 μm/y.
Collapse
Affiliation(s)
- Andrew J Carradus
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Olivier Mougin
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Benjamin A E Hunt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Prejaas K Tewarie
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Nicolas Geades
- Philips Clinical Science, Philips Healthcare, Eindhoven, the Netherlands
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Penny A Gowland
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Christopher R Madan
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK; School of Psychology, University of Nottingham, Nottingham, UK.
| |
Collapse
|
7
|
Fernandes CC, Lanz B, Chen C, Morris PG. Measurement of brain lactate during visual stimulation using a long TE semi-LASER sequence at 7 T. NMR Biomed 2020; 33:e4223. [PMID: 31995265 PMCID: PMC7079106 DOI: 10.1002/nbm.4223] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 10/21/2019] [Accepted: 10/22/2019] [Indexed: 05/14/2023]
Abstract
Estimation of metabolic changes during neuronal activation represents a challenge for in vivo MRS, especially for metabolites with low concentration and signal overlap, such as lactate. In this work, we aimed to evaluate the feasibility of detecting lactate during brain activation using a long TE (144 ms) semi-LASER sequence at 7 T. 1H spectra were acquired on healthy volunteers ( N=6 ) during a paradigm with 15 min of visual stimulation. Outer-volume signals were further attenuated by the use of saturation slabs, and macromolecular signals in the vicinity of the inverted lactate peak were individually fitted with simulated Lorentzian peaks. All spectra were free of artefacts and highly reproducible across subjects. Lactate was accurately quantified with an average Cramér-Rao lower bound of 8%. Statistically significant ( P<0.05 , one-tailed t -test) increases in lactate ( ∼ 10%) and glutamate ( ∼ 3%) levels during stimulation were detected in the visual cortex. Lactate and glutamate changes were consistent with previous measurements. We demonstrated that quantification of a clear and non-contaminated lactate peak obtained with a long TE sequence has the potential of improving the accuracy of functional MRS studies targeting non-oxidative reaction pathways.
Collapse
Affiliation(s)
- Carolina C. Fernandes
- Sir Peter Mansfield Imaging CentreUniversity of NottinghamNottingham, NG7 2RDNottinghamshireUnited Kingdom
| | - Bernard Lanz
- Sir Peter Mansfield Imaging CentreUniversity of NottinghamNottingham, NG7 2RDNottinghamshireUnited Kingdom
| | - Chen Chen
- Sir Peter Mansfield Imaging CentreUniversity of NottinghamNottingham, NG7 2RDNottinghamshireUnited Kingdom
| | - Peter G. Morris
- Sir Peter Mansfield Imaging CentreUniversity of NottinghamNottingham, NG7 2RDNottinghamshireUnited Kingdom
| |
Collapse
|
8
|
Skinner JG, Ranta K, Whiting N, Coffey AM, Nikolaou P, Rosen MS, Chekmenev EY, Morris PG, Barlow MJ, Goodson BM. High Xe density, high photon flux, stopped-flow spin-exchange optical pumping: Simulations versus experiments. J Magn Reson 2020; 312:106686. [PMID: 32006793 PMCID: PMC7436892 DOI: 10.1016/j.jmr.2020.106686] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Accepted: 01/07/2020] [Indexed: 05/13/2023]
Abstract
Spin-exchange optical pumping (SEOP) can enhance the NMR sensitivity of noble gases by up to five orders of magnitude at Tesla-strength magnetic fields. SEOP-generated hyperpolarised (HP) 129Xe is a promising contrast agent for lung imaging but an ongoing barrier to widespread clinical usage has been economical production of sufficient quantities with high 129Xe polarisation. Here, the 'standard model' of SEOP, which was previously used in the optimisation of continuous-flow 129Xe polarisers, is modified for validation against two Xe-rich stopped-flow SEOP datasets. We use this model to examine ways to increase HP Xe production efficiency in stopped-flow 129Xe polarisers and provide further insight into the underlying physics of Xe-rich stopped-flow SEOP at high laser fluxes.
Collapse
Affiliation(s)
- Jason G Skinner
- Division of Respiratory Medicine, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK
| | - Kaili Ranta
- Department of Chemistry and Biochemistry, Southern Illinois University Carbondale, Carbondale, IL, 62901, USA
| | - Nicholas Whiting
- Department of Physics & Astronomy and Department of Molecular & Cellular Biosciences, Rowan University, Glassboro, NJ 08028, USA
| | - Aaron M Coffey
- Vanderbilt University Institute of Imaging Science (VUIIS), Department of Radiology and Radiological Sciences, Vanderbilt-Ingram Cancer Center (VICC), Department of Biomedical Engineering, Department of Physics and Astronomy, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | | | - Matthew S Rosen
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA; Department of Radiology, Harvard Medical School, Boston, MA 02115, USA; Department of Physics, Harvard University, Cambridge, MA 02138, USA
| | - Eduard Y Chekmenev
- Russian Academy of Sciences, Leninskiy Prospekt 14, 119991 Moscow, Russia; Department of Chemistry, Integrative Biosciences (Ibio), Wayne State University, Karmanos Cancer Institute (KCI), Detroit, MI, 48202, United States
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics & Astronomy, University of Nottingham, Nottingham, NG7 2RD, UK
| | - Michael J Barlow
- Division of Respiratory Medicine, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK
| | - Boyd M Goodson
- Department of Chemistry and Biochemistry, Southern Illinois University Carbondale, Carbondale, IL, 62901, USA.
| |
Collapse
|
9
|
Seedat ZA, Quinn AJ, Vidaurre D, Liuzzi L, Gascoyne LE, Hunt BAE, O'Neill GC, Pakenham DO, Mullinger KJ, Morris PG, Woolrich MW, Brookes MJ. The role of transient spectral 'bursts' in functional connectivity: A magnetoencephalography study. Neuroimage 2020; 209:116537. [PMID: 31935517 DOI: 10.1016/j.neuroimage.2020.116537] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Revised: 12/02/2019] [Accepted: 01/10/2020] [Indexed: 12/29/2022] Open
Abstract
Neural oscillations dominate electrophysiological measures of macroscopic brain activity and fluctuations in these rhythms offer an insightful window on cortical excitation, inhibition, and connectivity. However, in recent years the 'classical' picture of smoothly varying oscillations has been challenged by the idea that many 'oscillations' may actually be formed from the recurrence of punctate high-amplitude bursts in activity, whose spectral composition intersects the traditionally defined frequency ranges (e.g. alpha/beta band). This finding offers a new interpretation of measurable brain activity, however neither the methodological means to detect bursts, nor their link to other findings (e.g. connectivity) have been settled. Here, we use a new approach to detect bursts in magnetoencephalography (MEG) data. We show that a time-delay embedded Hidden Markov Model (HMM) can be used to delineate single-region bursts which are in agreement with existing techniques. However, unlike existing techniques, the HMM looks for specific spectral patterns in timecourse data. We characterise the distribution of burst duration, frequency of occurrence and amplitude across the cortex in resting state MEG data. During a motor task we show how the movement related beta decrease and post movement beta rebound are driven by changes in burst occurrence. Finally, we show that the beta band functional connectome can be derived using a simple measure of burst overlap, and that coincident bursts in separate regions correspond to a period of heightened coherence. In summary, this paper offers a new methodology for burst identification and connectivity analysis which will be important for future investigations of neural oscillations.
Collapse
Affiliation(s)
- Zelekha A Seedat
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Andrew J Quinn
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, UK
| | - Diego Vidaurre
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, UK; Department of Clinical Medicine, Palle Juul-Jensens Boulevard 82, Building 2, Incuba/Skejby, 8200 Aarhus N, Denmark
| | - Lucrezia Liuzzi
- Mood Brain and Development Unit, Emotion and Development Branch, NIH/NIMH, Bethesda, MD 20892, USA
| | - Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Benjamin A E Hunt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK; Diagnostic Imaging, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada
| | - George C O'Neill
- Wellcome Centre for Human Neuroimaging, University College London, 12 Queen Square, London, WC1N 3AR, UK
| | - Daisie O Pakenham
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Karen J Mullinger
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK; Centre for Human Brain Health, School of Psychology, University of Birmingham, Birmingham, B15 2TT, UK
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, UK
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK.
| |
Collapse
|
10
|
Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, Simmonite M, Fiesal J, Katshu MZ, Qureshi A, Skelton M, Christodoulou NG, Brookes MJ, Morris PG, Liddle PF. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry 2020; 25:873-882. [PMID: 29934548 PMCID: PMC7156342 DOI: 10.1038/s41380-018-0104-7] [Citation(s) in RCA: 91] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Revised: 05/04/2018] [Accepted: 05/14/2018] [Indexed: 12/21/2022]
Abstract
In schizophrenia, abnormal neural metabolite concentrations may arise from cortical damage following neuroinflammatory processes implicated in acute episodes. Inflammation is associated with increased glutamate, whereas the antioxidant glutathione may protect against inflammation-induced oxidative stress. We hypothesized that patients with stable schizophrenia would exhibit a reduction in glutathione, glutamate, and/or glutamine in the cerebral cortex, consistent with a post-inflammatory response, and that this reduction would be most marked in patients with "residual schizophrenia", in whom an early stage with positive psychotic symptoms has progressed to a late stage characterized by long-term negative symptoms and impairments. We recruited 28 patients with stable schizophrenia and 45 healthy participants matched for age, gender, and parental socio-economic status. We measured glutathione, glutamate and glutamine concentrations in the anterior cingulate cortex (ACC), left insula, and visual cortex using 7T proton magnetic resonance spectroscopy (MRS). Glutathione and glutamate were significantly correlated in all three voxels. Glutamine concentrations across the three voxels were significantly correlated with each other. Principal components analysis (PCA) produced three clear components: an ACC glutathione-glutamate component; an insula-visual glutathione-glutamate component; and a glutamine component. Patients with stable schizophrenia had significantly lower scores on the ACC glutathione-glutamate component, an effect almost entirely leveraged by the sub-group of patients with residual schizophrenia. All three metabolite concentration values in the ACC were significantly reduced in this group. These findings are consistent with the hypothesis that excitotoxicity during the acute phase of illness leads to reduced glutathione and glutamate in the residual phase of the illness.
Collapse
Affiliation(s)
- Jyothika Kumar
- 0000 0004 1936 8868grid.4563.4Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK
| | - Elizabeth B. Liddle
- 0000 0004 1936 8868grid.4563.4Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK
| | - Carolina C. Fernandes
- 0000 0004 1936 8868grid.4563.4Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - Lena Palaniyappan
- 0000 0004 1936 8884grid.39381.30Departments of Psychiatry, Medical Biophysics and Neuroscience, Western University, London, ON Canada ,Lawson Research, Brain and Mind & Robarts Research Institutes, London, ON Canada
| | - Emma L. Hall
- 0000 0004 1936 8868grid.4563.4Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - Siân E. Robson
- 0000 0000 8610 2323grid.482042.8Healthcare Improvement Scotland, Gyle Square, Edinburgh, UK
| | - Molly Simmonite
- 0000000086837370grid.214458.eDepartment of Psychology, University of Michigan, Ann Arbor, MI USA
| | - Jan Fiesal
- grid.500956.fSouth Staffordshire and Shropshire Healthcare NHS Foundation Trust, Stafford, UK
| | - Mohammad Z. Katshu
- 0000 0004 1936 8868grid.4563.4Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK ,0000 0001 1514 761Xgrid.439378.2Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
| | - Ayaz Qureshi
- 0000 0004 0430 6955grid.450837.dGreater Manchester West Mental Health NHS Foundation Trust, Manchester, UK
| | - Michael Skelton
- 0000 0004 0396 1667grid.418388.eDerbyshire Healthcare NHS Foundation Trust, Derby, UK
| | - Nikolaos G. Christodoulou
- 0000 0004 1936 8868grid.4563.4Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK ,0000 0001 1514 761Xgrid.439378.2Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
| | - Matthew J. Brookes
- 0000 0004 1936 8868grid.4563.4Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - Peter G. Morris
- 0000 0004 1936 8868grid.4563.4Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - Peter F. Liddle
- 0000 0004 1936 8868grid.4563.4Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK
| |
Collapse
|
11
|
Hunt BAE, Liddle EB, Gascoyne LE, Magazzini L, Routley BC, Singh KD, Morris PG, Brookes MJ, Liddle PF. Attenuated Post-Movement Beta Rebound Associated With Schizotypal Features in Healthy People. Schizophr Bull 2019; 45:883-891. [PMID: 30239878 PMCID: PMC6581139 DOI: 10.1093/schbul/sby117] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Schizophrenia and schizotypal personality disorder (SPD) lie on a single spectrum of mental illness and converging evidence suggests similarities in the etiology of the 2 conditions. However, schizotypy is a heterogeneous facet of personality in the healthy population and so may be seen as a bridge between health and mental illness. Neural evidence for such a continuity would have implications for the characterization and treatment of schizophrenia. Based on our previous work identifying a relationship between symptomology in schizophrenia and abnormal movement-induced electrophysiological response (the post-movement beta rebound [PMBR]), we predicted that if subclinical schizotypy arises from similar neural mechanisms to schizophrenia, schizotypy in healthy individuals would be associated with reduced PMBR. METHODS One-hundred sixteen participants completed a visuomotor task while their neural activity was recorded by magnetoencephalography. Partial correlations were computed between a measure of PMBR extracted from left primary motor cortex and scores on the Schizotypal Personality Questionnaire (SPQ), a self-report measure of schizotypal personality. Correlations between PMBR and SPQ factor scores measuring cognitive-perceptual, interpersonal and disorganization dimensions of schizotypy were also computed. Effects of site, age, and sex were controlled for. RESULTS We found a significant negative correlation between total SPQ score and PMBR. This was most strongly mediated by variance shared between interpersonal and disorganization factor scores. CONCLUSION These findings indicate a continuum of neural deficit between schizotypy and schizophrenia, with diminution of PMBR, previously reported in schizophrenia, also measurable in individuals with schizotypal features, particularly disorganization and impaired interpersonal relations.
Collapse
Affiliation(s)
- Benjamin A E Hunt
- Diagnostic Imaging, The Hospital for Sick Children, Toronto, ON, Canada
- Program in Neurosciences and Mental Health, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
- The Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - Elizabeth B Liddle
- The Institute for Mental Health, University of Nottingham, Nottingham, UK
| | - Lauren E Gascoyne
- Program in Neurosciences and Mental Health, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
| | - Lorenzo Magazzini
- Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK
| | - Bethany C Routley
- Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK
| | - Krish D Singh
- Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK
| | - Peter G Morris
- Program in Neurosciences and Mental Health, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
| | - Matthew J Brookes
- Program in Neurosciences and Mental Health, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
| | - Peter F Liddle
- The Institute for Mental Health, University of Nottingham, Nottingham, UK
| |
Collapse
|
12
|
Hassan A, Gullo G, O'Reilly S, Ruiz-Borrego M, Toomey S, Grogan L, Breathnach O, Morris PG, Walshe JM, Crown J, O'Mahony D, Falcon A, Egan K, Hernando A, Teiserskiene A, Kelly CM, Coate L, Hennessy BT. Abstract OT3-06-01: Phase Ib clinical trial of co PANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive bre Ast cancer (BC) “PANTHERA”-CTRIAL-IE 17-13. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-06-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrant activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 positive breast cancer having a PIK3CA mutation. Copanlisib is a pan-class 1 PI3K inhibitor administered i.v. with low nanomolar activity against both PI3Kα and PI3Kβ. Copanlisib has been shown to re-sensitise trastuzumab resistant cell lines to trastuzumab with synergism seen in some cell lines between copanlisib and HER2 targeted therapy.
Trial design: This is a phase Ib open label, single arm adaptive, multi-centre trial of copanlisib in combination with T-DM1. Eligible patients will receive T-DM1 at 3.6mg/kg i.v. on day 1 of a 21-day cycle plus copanlisib. Copanlisib will be administered i.v. according to the dose escalation scheme (dose level 1 is 45mg on days 1 and 8, dose level 2 is 60mg on days 1 and 8, dose level 3 is 60mg on days 1, 8, and 15). Dose level -1 will be 45 mg on day 1 in case dose de-escalation is needed. We will enrol 3 to 6 patients per dose level. All patients in each level must have completed at least the first cycle of therapy before enrolment in the next dose level. Patients not completing the first cycle for a reason other than toxicity will be replaced. Dose escalation and determination of the Maximum Tolerated Dose (MTD) will be based on the occurrence of Dose Limiting Toxicities (DLT).
Eligibility criteria:Eligible patients are those with unresectable locally advanced or metastatic HER2-positive BC who previously received trastuzumab and a taxane, separately or in combination. Participants must have adequate organ function and ECOG PS ≤ 2
Objectives:The primary objective is to determine the MTD for copanlisib in combination with T-DM1 in patients with pre-treated unresectable locally advanced or metastatic HER2-positive BC. Secondary objectives include evaluating the safety, efficacy and cardiotoxicity in patients treated with this regimen. Exploratory objectives include examining for predictive biomarkers in tumour tissue and blood or plasma and to examine molecular tumour adaptation to clinical trial therapy.
Statistical methods: Patients will be accrued in cohorts of 3 patients according to a standard 3+3 algorithm, with dose escalation and determination of MTD based on the occurrence of DLT, using the usual threshold probability of 33%. The final dose level will be expanded to include a total of 6 additional patients (expansion cohort).
Present accrual and target accrual:The trial will start accrual in October 2018. Maximum of 24 patients will be enrolled.
Citation Format: Hassan A, Gullo G, O'Reilly S, Ruiz-Borrego M, Toomey S, Grogan L, Breathnach O, Morris PG, Walshe JM, Crown J, O'Mahony D, Falcon A, Egan K, Hernando A, Teiserskiene A, Kelly CM, Coate L, Hennessy BT. Phase Ib clinical trial of coPANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive breAst cancer (BC) “PANTHERA”-CTRIAL-IE 17-13 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-06-01.
Collapse
Affiliation(s)
- A Hassan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - G Gullo
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - S O'Reilly
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - M Ruiz-Borrego
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - S Toomey
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - L Grogan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - O Breathnach
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - PG Morris
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - JM Walshe
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - J Crown
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - D O'Mahony
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Falcon
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - K Egan
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Hernando
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - A Teiserskiene
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - CM Kelly
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - L Coate
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| | - BT Hennessy
- RCSI, Dublin 9, Ireland; Beaumont Hospital, Dublin 9, Ireland; St Vincent's University Hospital, Dublin 4, Ireland; Cork University Hospital, Cork, Ireland; Hospital Universitario Virgen Del Rocío, Sevilla, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland
| |
Collapse
|
13
|
Briley PM, Liddle EB, Groom MJ, Smith HJF, Morris PG, Colclough GL, Brookes MJ, Liddle PF. Development of human electrophysiological brain networks. J Neurophysiol 2018; 120:3122-3130. [PMID: 30354795 PMCID: PMC6337030 DOI: 10.1152/jn.00293.2018] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Functional activity in the human brain is intrinsically organized into independently active, connected brain regions. These networks include sensorimotor systems, as well as higher-order cognitive networks such as the default mode network (DMN), which dominates activity when the brain is at rest, and the frontoparietal (FPN) and salience (SN) networks, which are often engaged during demanding tasks. Evidence from functional magnetic resonance imaging (fMRI) suggests that although sensory systems are mature by the end of childhood, the integrity of the FPN and SN develops throughout adolescence. There has been little work to corroborate these findings with electrophysiology. Using magnetoencephalography (MEG) recordings of 48 participants (aged 9–25 yr) at rest, we find that beta-band functional connectivity within the FPN, SN, and DMN continues to increase through adolescence, whereas connectivity in the visual system is mature by late childhood. In contrast to fMRI results, but replicating the MEG findings of Schäfer et al. (Schäfer CB, Morgan BR, Ye AX, Taylor MJ, Doesburg SM. Hum Brain Mapp 35: 5249–5261, 2014), we also see that connectivity between networks increases rather than decreases with age. This suggests that the development of coordinated beta-band oscillations within and between higher-order cognitive networks through adolescence might contribute to the developing abilities of adolescents to focus their attention and coordinate diverse aspects of mental activity. NEW & NOTEWORTHY Using magnetoencephalography to assess beta frequency oscillations, we show that functional connectivity within higher-order cognitive networks increases from childhood, reaching adult values by age 20 yr. In contrast, connectivity within a primary sensory (visual) network reaches adult values by age 14 yr. In contrast to functional MRI findings, connectivity between cognitive networks matures at a rate similar to within-network connectivity, suggesting that coordination of beta oscillations both within and between networks is associated with maturation of cognitive skills.
Collapse
Affiliation(s)
- Paul M Briley
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham , Nottingham , United Kingdom
| | - Elizabeth B Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham , Nottingham , United Kingdom
| | - Madeleine J Groom
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham , Nottingham , United Kingdom
| | - Helen J F Smith
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham , Nottingham , United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham , Nottingham , United Kingdom
| | - Giles L Colclough
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford , Oxford , United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham , Nottingham , United Kingdom
| | - Peter F Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham , Nottingham , United Kingdom
| |
Collapse
|
14
|
Gascoyne LE, Mullinger KJ, Robson SE, Kumar J, O'Neill GC, Palaniyappan L, Morris PG, Liddle EB, Brookes MJ, Liddle PF. Changes in electrophysiological markers of cognitive control after administration of galantamine. Neuroimage Clin 2018; 20:228-235. [PMID: 30090697 PMCID: PMC6078055 DOI: 10.1016/j.nicl.2018.07.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 06/12/2018] [Accepted: 07/21/2018] [Indexed: 02/01/2023]
Abstract
The healthy brain is able to maintain a stable balance between bottom-up sensory processing and top-down cognitive control. The neurotransmitter acetylcholine plays a substantial role in this. Disruption of this balance could contribute to symptoms occurring in psychosis, including subtle disruption of motor control and aberrant appropriation of salience to external stimuli; however the pathological mechanisms are poorly understood. On account of the role beta oscillations play in mediating cognitive control, investigation of beta oscillations is potentially informative about such mechanisms. Here, we used magnetoencephalography to investigate the effect of the acetylcholinesterase-inhibitor, galantamine, on beta oscillations within the sensorimotor region during both a sensorimotor task and a relevance-modulation task in healthy participants, employing a double blind randomized placebo controlled cross-over design. In the galantamine condition, we found a significant reduction in the post-movement beta rebound in the case of executed movements and also in a planned but not executed movement. In the latter case, the effect was significantly greater following task-relevant compared with irrelevant stimuli. The results suggest that the action of galantamine reduces the influence of top-down cognitive processing relative to bottom-up perceptual processing in a manner resembling changes previously reported in schizophrenia.
Collapse
Affiliation(s)
- Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK.
| | - Karen J Mullinger
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Siân E Robson
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Jyothika Kumar
- Institute of Mental Health, Jubilee Campus, University of Nottingham, Nottingham, UK
| | - George C O'Neill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Lena Palaniyappan
- Department of Psychiatry & Robarts Research Institute, University of Western Ontario & Lawson Health Research Institute, London, ON, Canada
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Elizabeth B Liddle
- Institute of Mental Health, Jubilee Campus, University of Nottingham, Nottingham, UK
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Peter F Liddle
- Institute of Mental Health, Jubilee Campus, University of Nottingham, Nottingham, UK.
| |
Collapse
|
15
|
Brookes MJ, Groom MJ, Liuzzi L, Hill RM, Smith HJF, Briley PM, Hall EL, Hunt BAE, Gascoyne LE, Taylor MJ, Liddle PF, Morris PG, Woolrich MW, Liddle EB. Altered temporal stability in dynamic neural networks underlies connectivity changes in neurodevelopment. Neuroimage 2018; 174:563-575. [PMID: 29524625 DOI: 10.1016/j.neuroimage.2018.03.008] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 03/02/2018] [Accepted: 03/03/2018] [Indexed: 01/02/2023] Open
Abstract
Network connectivity is an integral feature of human brain function, and characterising its maturational trajectory is a critical step towards understanding healthy and atypical neurodevelopment. Here, we used magnetoencephalography (MEG) to investigate both stationary (i.e. time averaged) and rapidly modulating (dynamic) electrophysiological connectivity, in participants aged from mid-childhood to early adulthood (youngest participant 9 years old; oldest participant 25 years old). Stationary functional connectivity (measured via inter-regional coordination of neural oscillations) increased with age in the alpha and beta frequency bands, particularly in bilateral parietal and temporo-parietal connections. Our dynamic analysis (also applied to alpha/beta oscillations) revealed the spatiotemporal signatures of 8 dynamic networks; these modulate on a ∼100 ms time scale, and temporal stability in attentional networks was found to increase with age. Significant overlap was found between age-modulated dynamic networks and inter-regional oscillatory coordination, implying that altered network dynamics underlie age related changes in functional connectivity. Our results provide novel insights into brain network electrophysiology, and lay a foundation for future work in childhood disorders.
Collapse
Affiliation(s)
- Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
| | - Madeleine J Groom
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, UK
| | - Lucrezia Liuzzi
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Ryan M Hill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Helen J F Smith
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, UK
| | - Paul M Briley
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, UK
| | - Emma L Hall
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Benjamin A E Hunt
- Diagnostic Imaging, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; Neurosciences and Mental Health Program, The Hospital for Sick Children Research Institute, Toronto M5G0A4, Canada
| | - Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Margot J Taylor
- Diagnostic Imaging, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; Department of Medical Imaging, University of toronto, Toronto M5T1W7, Canada
| | - Peter F Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, UK
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, United Kingdom
| | - Elizabeth B Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, UK
| |
Collapse
|
16
|
Barratt EL, Francis ST, Morris PG, Brookes MJ. Mapping the topological organisation of beta oscillations in motor cortex using MEG. Neuroimage 2018; 181:831-844. [PMID: 29960087 PMCID: PMC6150950 DOI: 10.1016/j.neuroimage.2018.06.041] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 06/05/2018] [Accepted: 06/12/2018] [Indexed: 12/19/2022] Open
Abstract
The spatial topology of the human motor cortex has been well studied, particularly using functional Magnetic Resonance Imaging (fMRI) which allows spatial separation of haemodynamic responses arising from stimulation of different body parts, individual digits and even spatially separate areas of the same digit. However, the spatial organisation of electrophysiological responses, particularly neural oscillations (rhythmic changes in electrical potential across cellular assemblies) has been less well studied. Mapping the spatial signature of neural oscillations is possible using magnetoencephalography (MEG), however spatial differentiation of responses induced by movement of separate digits is a challenge, because the brain regions involved are separated by only a few millimetres. In this paper we first show, in simulation, how to optimise experimental design and beamformer spatial filtering techniques to increase the spatial specificity of MEG derived functional images. Combining this result with experimental data, we then capture the organisation of the post-movement beta band (13–30 Hz) oscillatory response to movement of digits 2 and 5 of the dominant hand, in individual subjects. By comparing these MEG results to ultra-high field (7T) fMRI, we also show significant spatial agreement between beta modulation and the blood oxygenation level dependent (BOLD) response. Our results show that, when using an optimised inverse solution and controlling subject movement (using custom fitted foam padding) the spatial resolution of MEG can be of order 3–5 mm. The method described offers exciting potential to understand better the cortical organisation of oscillations, and to probe such organisation in patient populations where those oscillations are known to be abnormal. Aim is to map the topological organisation of neural oscillations in motor cortex. MEG spatial resolution optimised by temporal separation of sources. Subject motion controlled using foam headcasts. Cortical representation of Digit 2 and Digit 5 separated spatially. Post movement beta rebound maps motortopically in agreement with BOLD responses.
Collapse
Affiliation(s)
- Eleanor L Barratt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Susan T Francis
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
| |
Collapse
|
17
|
Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. Abstract OT3-06-05: A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The phosphoinositide 3 kinase (PI3K) pathway is important in the oncogenic function of HER2. Aberrent activation of PI3K is implicated in resistance to trastuzumab and other HER2-targeted therapies and is frequent, with up to 22% of HER2 positive breast cancer having a PIK3CA mutation. Copanlisib is a pan-class 1 PI3K inhibitor that shows particular activity against PI3Kα, the isoform encoded by the PIK3CA gene. Copanlisib has been shown to re-sensitise trastuzumab resistant cell lines to trastuzumab with synergism seen in some cell lines between copanlisib and HER2 targeted therapy.
Trial design
The study is a phase Ib/II open label, single arm adaptive, multi-centre trial of copanlisib in combination with trastuzumab. Eligible patients are treated with a dose escalation schedule of copanlisib IV on Days 1, 8 and 15 of a 28 day cycle with trastuzumab 2 mg/kg weekly (loading dose of 4 mg/kg in cycle 1). The phase II dose will be based on the maximum tolerated dose (MTD) established in Phase Ib. Patients are treated until radiologic or symptomatic progression, unacceptable toxicity, consent withdrawal or physician's decision.
Eligibility criteria
Eligible patients must have recurrent incurable or metastatic HER2-positive breast cancer that has progressed on at least one prior line of trastuzumab or T-DM1-based treatment regimen in this setting. Patients with treated and controlled brain metastases are eligible. Participants must have adequate organ function and ECOG PS ≤ 2. Patients recruited for the Phase II part of the study must have a PIK3CA mutation. Patients with uncontrolled arterial hypertension, uncontrolled diabetes or recent clinically serious infections are excluded.
Specific aims
The primary end point for the phase Ib part of this study is to determine the MTD for the combination. For the phase II study is anti-tumour efficacy, measured by Clinical Benefit Rate (CBR).
Secondary end points are evaluation of safety and tolerability, progression-free survival, time to treatment failure, duration of response and overall survival. Incorporated translational endpoints include examination of molecular tumor adaptation in tissue and blood. Given the role of PI3K in cellular glucose metabolism, an additional exploratory objective is to determine if quantitive reduction in metabolic signal on Positron Emission Tomography-Computed Tomography (PET-CT) is predictive of benefit from therapy.
Statistical methods
To establish the MTD, we use a modified 3+3 design where 3 additional patients will be accrued even if the first 3 patients accrued experience no dose limiting toxicities (DLT) in sequential cohorts for a planned 12 patients. To determine the CBR, a one sample exact binomial test with a one sided significance level of 5%, 19 evaluable patients will provide >80% power to detect a difference between the null hypothesis proportion of 30% for CBR versus the alternative hypothesis proportion of 65%.
Present accrual and target accrual
There are 9 patients recruited so far to the phase Ib part of this study. Target accrual is 12 and for phase II is 19 patients.
Contact information for people with a specific interest in the trial
Prof Bryan Hennessy, Beaumont Hospital, Dublin Ireland
Funded by Bayer
Citation Format: Keegan NM, Walshe J, Gullo G, Kennedy J, Bulger K, Kelly CM, Crown J, Toomey S, Egan K, Kerr J, Given M, Hernando A, Teiserskiene A, Grogan L, Breathnach O, Morris PG, Keane M, Hennessy BT. A phase Ib/II trial of coPANlisib in combination with tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER” [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-06-05.
Collapse
Affiliation(s)
- NM Keegan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Walshe
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - G Gullo
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kennedy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Bulger
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - CM Kelly
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Crown
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - S Toomey
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - K Egan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - J Kerr
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Given
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Hernando
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - A Teiserskiene
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - L Grogan
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - O Breathnach
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - PG Morris
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - M Keane
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| | - BT Hennessy
- RCSI Molecular Medicine, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; St James's Hospital, Dublin, Ireland; Midland Regional Hospital at Tullamore, Tullamore, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Clinical Trials & Research Unit, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland; Galway University Hospital, Galway, Ireland
| |
Collapse
|
18
|
Chen C, Stephenson MC, Peters A, Morris PG, Francis ST, Gowland PA. 31 P magnetization transfer magnetic resonance spectroscopy: Assessing the activation induced change in cerebral ATP metabolic rates at 3 T. Magn Reson Med 2017; 79:22-30. [PMID: 28303591 PMCID: PMC5706641 DOI: 10.1002/mrm.26663] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Revised: 02/05/2017] [Accepted: 02/09/2017] [Indexed: 12/19/2022]
Abstract
Purpose In vivo 31P magnetic resonance spectroscopy (MRS) magnetization transfer (MT) provides a direct measure of neuronal activity at the metabolic level. This work aims to use functional 31P MRS‐MT to investigate the change in cerebral adenosine triphosphate (ATP) metabolic rates in healthy adults upon repeated visual stimuli. Methods A magnetization saturation transfer sequence with narrowband selective saturation of γ‐ATP was developed for 31P MT experiments at 3 T. Results Using progressive saturation of γ‐ATP, the intrinsic T1 relaxation times of phosphocreatine (PCr) and inorganic phosphate (Pi) at 3 T were measured to be 5.1 ± 0.8 s and 3.0 ± 1.4 s, respectively. Using steady‐state saturation of γ‐ATP, a significant 24% ± 14% and 11% ± 7% increase in the forward creatine kinase (CK) pseudo‐first‐order reaction rate constant, k1, was observed upon visual stimulation in the first and second cycles, respectively, of a paradigm consisting of 10‐minute rest followed by 10‐minute stimulation, with the measured baseline k1 being 0.35 ± 0.04 s−1. No significant changes in forward ATP synthase reaction rate, PCr/γ‐ATP, Pi/γ‐ATP, and nicotinamide adenine dinucleotide/γ‐ATP ratios, or intracellular pH were detected upon stimulation. Conclusion This work demonstrates the potential of studying cerebral bioenergetics using functional 31P MRS‐MT to determine the change in the forward CK reaction rate at 3 T. Magn Reson Med 79:22–30, 2018. © 2017 The Authors Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Collapse
Affiliation(s)
- Chen Chen
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| | - Mary C Stephenson
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| | - Andrew Peters
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| | - Susan T Francis
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| | - Penny A Gowland
- Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, Nottinghamshire, United Kingdom
| |
Collapse
|
19
|
Barratt EL, Tewarie PK, Clarke MA, Hall EL, Gowland PA, Morris PG, Francis ST, Evangelou N, Brookes MJ. Abnormal task driven neural oscillations in multiple sclerosis: A visuomotor MEG study. Hum Brain Mapp 2017; 38:2441-2453. [PMID: 28240392 PMCID: PMC6866959 DOI: 10.1002/hbm.23531] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 12/20/2016] [Accepted: 01/17/2017] [Indexed: 01/14/2023] Open
Abstract
Multiple sclerosis (MS) is a debilitating disease commonly attributed to degradation of white matter myelin. Symptoms include fatigue, as well as problems associated with vision and movement. Although areas of demyelination in white matter are observed routinely in patients undergoing MRI scans, such measures are often a poor predictor of disease severity. For this reason, it is instructive to measure associated changes in brain function. Widespread white‐matter demyelination may lead to delays of propagation of neuronal activity, and with its excellent temporal resolution, magnetoencephalography can be used to probe such delays in controlled conditions (e.g., during a task). In healthy subjects, responses to visuomotor tasks are well documented: in motor cortex, movement elicits a localised decrease in the power of beta band oscillations (event‐related beta desynchronisation) followed by an increase above baseline on movement cessation (post‐movement beta rebound (PMBR)). In visual cortex, visual stimulation generates increased gamma oscillations. In this study, we use a visuomotor paradigm to measure these responses in MS patients and compare them to age‐ and gender‐matched healthy controls. We show a significant increase in the time‐to‐peak of the PMBR in patients which correlates significantly with the symbol digit modalities test: a measure of information processing speed. A significant decrease in the amplitude of visual gamma oscillations in patients is also seen. These findings highlight the potential value of electrophysiological imaging in generating a new understanding of visual disturbances and abnormal motor control in MS patients. Hum Brain Mapp 38:2441–2453, 2017. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Eleanor L Barratt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Prejaas K Tewarie
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Margareta A Clarke
- Division of Clinical Neurology, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom
| | - Emma L Hall
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Penny A Gowland
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Susan T Francis
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| | - Nikos Evangelou
- Division of Clinical Neurology, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom
| |
Collapse
|
20
|
Keegan NM, Milewski M, Kelly CM, Murphy V, Chao C, Walsh J, Kennedy MJ, O'Connor M, Murphy C, O'Reilly S, Keane M, Duffy K, Hennessy B, Morris PG. Abstract OT3-04-03: The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-04-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND
For Estrogen Receptor (ER) positive, early stage breast cancer, the 21 gene Recurrence Score (RS) has clinical use both as a prognostic tool and to predict chemotherapy benefit. The availability of this tool in Ireland has led to a reduction in the use of adjuvant chemotherapy for women with lymph node (LN) negative disease. However, the RS is not routinely funded for patients with LN positive (LN+) breast cancer in Ireland. In addition, there are limited international data on the use of this tool in the preoperative setting. In this prospective observational study, we are investigating whether access to the 21 gene RS leads to a reduction in the receipt of chemotherapy for patients with ER+, LN+ breast cancer, and to correlate the 21 gene RS with response to preoperative systemic therapy.
TRIAL DESIGN
This is a national, multi-site, prospective, observational study that will examine the impact of the 21 gene RS on chemotherapy recommendations in both the neoadjuvant and adjuvant setting. Prior to and following tumor testing with the 21 gene RS, Physicians will complete a questionnaire which details type and strength of systemic therapy recommendations.
ELIGIBILITY
Cohort 1 (postoperative) will include patients with ER+ tumors of any size with involvement of 1-3 lymph nodes (N1 including micrometastases). Cohort 2 (preoperative) will include patients with ER+, T2-T4 tumors with biopsy proven nodal metastases. Both cohorts will have ECOG PS 0 or 1 and be fit for consideration of chemotherapy as determined by the Investigator.
SPECIFIC AIMS
The primary endpoint is the percentage reduction in the number of patients for whom treating physicians recommend chemotherapy after testing with 21 gene RS. Secondary endpoints include the correlation between the 21 gene RS and residual cancer burden score, as well as pathological, clinical and radiological response rates. The economic impact of the 21 gene RS in ER+, LN+ will also be assessed.
STATISTICAL METHODS
The sample size is based on similar decision impact studies conducted in other countries. Physician recommendations for chemotherapy pre 21-gene RS and recommendations post 21-gene RS testing will be compared and percentage change estimated with 95% confidence intervals. For secondary endpoints, the Pearson correlation coefficient (rho) will be used to examine the strength of the correlation between the 21 gene RS category and response. A budget impact model will be used to estimate the cost reduction in adjuvant chemotherapy as a result of 21-gene RS testing.
PRESENT ACCRUAL AND TARGET ACCRUAL
Target accrual is 75 in each of the neoadjuvant and adjuvant cohorts to total 150 patients.
Supported by Genomic Health.
Citation Format: Keegan NM, Milewski M, Kelly CM, Murphy V, Chao C, Walsh J, Kennedy MJ, O'Connor M, Murphy C, O'Reilly S, Keane M, Duffy K, Hennessy B, Morris PG. The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-03.
Collapse
Affiliation(s)
- NM Keegan
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M Milewski
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - CM Kelly
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - V Murphy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - C Chao
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - J Walsh
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - MJ Kennedy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M O'Connor
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - C Murphy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - S O'Reilly
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - M Keane
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - K Duffy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - B Hennessy
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| | - PG Morris
- Beaumont Hospital, Dublin 9, Ireland; Mater Misericordiae University Hospital, Dublin 7, Ireland; Cancer Trials Ireland, Dublin 2, Ireland; Genomic Health, Ireland; St James's Hospital, Dublin 8, Ireland; University Hospital Waterford, Waterford, Ireland; Bon Secours, Cork, Ireland; Cork University Hospital, Ireland; University College Hospital Galway, Ireland; Letterkenny General Hospital, Ireland; AMNCH and St Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
21
|
Boto E, Meyer SS, Shah V, Alem O, Knappe S, Kruger P, Fromhold TM, Lim M, Glover PM, Morris PG, Bowtell R, Barnes GR, Brookes MJ. A new generation of magnetoencephalography: Room temperature measurements using optically-pumped magnetometers. Neuroimage 2017; 149:404-414. [PMID: 28131890 PMCID: PMC5562927 DOI: 10.1016/j.neuroimage.2017.01.034] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 01/11/2017] [Accepted: 01/15/2017] [Indexed: 11/29/2022] Open
Abstract
Advances in the field of quantum sensing mean that magnetic field sensors, operating at room temperature, are now able to achieve sensitivity similar to that of cryogenically cooled devices (SQUIDs). This means that room temperature magnetoencephalography (MEG), with a greatly increased flexibility of sensor placement can now be considered. Further, these new sensors can be placed directly on the scalp surface giving, theoretically, a large increase in the magnitude of the measured signal. Here, we present recordings made using a single optically-pumped magnetometer (OPM) in combination with a 3D-printed head-cast designed to accurately locate and orient the sensor relative to brain anatomy. Since our OPM is configured as a magnetometer it is highly sensitive to environmental interference. However, we show that this problem can be ameliorated via the use of simultaneous reference sensor recordings. Using median nerve stimulation, we show that the OPM can detect both evoked (phase-locked) and induced (non-phase-locked oscillatory) changes when placed over sensory cortex, with signals ~4 times larger than equivalent SQUID measurements. Using source modelling, we show that our system allows localisation of the evoked response to somatosensory cortex. Further, source-space modelling shows that, with 13 sequential OPM measurements, source-space signal-to-noise ratio (SNR) is comparable to that from a 271-channel SQUID system. Our results highlight the opportunity presented by OPMs to generate uncooled, potentially low-cost, high SNR MEG systems.
Collapse
Affiliation(s)
- Elena Boto
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Sofie S Meyer
- Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, 12 Queen Square, London WC1N 3BG, United Kingdom
| | - Vishal Shah
- QuSpin Inc., 2011 Cherry Street, Unit 112, Louisville, CO 80027, USA
| | - Orang Alem
- QuSpin Inc., 2011 Cherry Street, Unit 112, Louisville, CO 80027, USA
| | - Svenja Knappe
- QuSpin Inc., 2011 Cherry Street, Unit 112, Louisville, CO 80027, USA
| | - Peter Kruger
- Midlands Ultracold Atom Research Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - T Mark Fromhold
- Midlands Ultracold Atom Research Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Mark Lim
- Chalk Studios Ltd., 14 Windsor Street, London N1 8QG, United Kingdom
| | - Paul M Glover
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Richard Bowtell
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Gareth R Barnes
- Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, 12 Queen Square, London WC1N 3BG, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.
| |
Collapse
|
22
|
Tewarie P, Hillebrand A, van Dijk BW, Stam CJ, O'Neill GC, Van Mieghem P, Meier JM, Woolrich MW, Morris PG, Brookes MJ. Integrating cross-frequency and within band functional networks in resting-state MEG: A multi-layer network approach. Neuroimage 2016; 142:324-336. [PMID: 27498371 DOI: 10.1016/j.neuroimage.2016.07.057] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 06/17/2016] [Accepted: 07/27/2016] [Indexed: 10/21/2022] Open
Abstract
Neuronal oscillations exist across a broad frequency spectrum, and are thought to provide a mechanism of interaction between spatially separated brain regions. Since ongoing mental activity necessitates the simultaneous formation of multiple networks, it seems likely that the brain employs interactions within multiple frequency bands, as well as cross-frequency coupling, to support such networks. Here, we propose a multi-layer network framework that elucidates this pan-spectral picture of network interactions. Our network consists of multiple layers (frequency-band specific networks) that influence each other via inter-layer (cross-frequency) coupling. Applying this model to MEG resting-state data and using envelope correlations as connectivity metric, we demonstrate strong dependency between within layer structure and inter-layer coupling, indicating that networks obtained in different frequency bands do not act as independent entities. More specifically, our results suggest that frequency band specific networks are characterised by a common structure seen across all layers, superimposed by layer specific connectivity, and inter-layer coupling is most strongly associated with this common mode. Finally, using a biophysical model, we demonstrate that there are two regimes of multi-layer network behaviour; one in which different layers are independent and a second in which they operate highly dependent. Results suggest that the healthy human brain operates at the transition point between these regimes, allowing for integration and segregation between layers. Overall, our observations show that a complete picture of global brain network connectivity requires integration of connectivity patterns across the full frequency spectrum.
Collapse
Affiliation(s)
- Prejaas Tewarie
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom.
| | - Arjan Hillebrand
- Department of Clinical Neurophysiology, MEG Center, VU University Medical Centre, Amsterdam, The Netherlands
| | - Bob W van Dijk
- Department of Clinical Neurophysiology, MEG Center, VU University Medical Centre, Amsterdam, The Netherlands
| | - Cornelis J Stam
- Department of Clinical Neurophysiology, MEG Center, VU University Medical Centre, Amsterdam, The Netherlands
| | - George C O'Neill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom
| | - Piet Van Mieghem
- Delft University of Technology, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft, The Netherlands
| | - Jil M Meier
- Delft University of Technology, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft, The Netherlands
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity (OHBA), University of Oxford, Oxford, United Kingdom; Centre for the Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, Oxford, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom
| |
Collapse
|
23
|
O'Neill GC, Tewarie PK, Colclough GL, Gascoyne LE, Hunt BAE, Morris PG, Woolrich MW, Brookes MJ. Measurement of dynamic task related functional networks using MEG. Neuroimage 2016; 146:667-678. [PMID: 27639354 PMCID: PMC5312793 DOI: 10.1016/j.neuroimage.2016.08.061] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2016] [Revised: 08/02/2016] [Accepted: 08/29/2016] [Indexed: 12/28/2022] Open
Abstract
The characterisation of dynamic electrophysiological brain networks, which form and dissolve in order to support ongoing cognitive function, is one of the most important goals in neuroscience. Here, we introduce a method for measuring such networks in the human brain using magnetoencephalography (MEG). Previous network analyses look for brain regions that share a common temporal profile of activity. Here distinctly, we exploit the high spatio-temporal resolution of MEG to measure the temporal evolution of connectivity between pairs of parcellated brain regions. We then use an ICA based procedure to identify networks of connections whose temporal dynamics covary. We validate our method using MEG data recorded during a finger movement task, identifying a transient network of connections linking somatosensory and primary motor regions, which modulates during the task. Next, we use our method to image the networks which support cognition during a Sternberg working memory task. We generate a novel neuroscientific picture of cognitive processing, showing the formation and dissolution of multiple networks which relate to semantic processing, pattern recognition and language as well as vision and movement. Our method tracks the dynamics of functional connectivity in the brain on a timescale commensurate to the task they are undertaking. A method is developed to track dynamic electrophysiological networks using MEG. Method based on ICA applied to timecourses measuring evolution of connectivity. Method allows a unique picture of transient networks that support cognition. Method validated in MEG data recorded during a Sternberg working memory task. Sensory networks observed include visual and sensorimotor. Cognitive networks relate to semantic processing, pattern recognition and language.
Collapse
Affiliation(s)
- George C O'Neill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Prejaas K Tewarie
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Giles L Colclough
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, UK; Oxford Centre for Functional MRI of the Brain, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Benjamin A E Hunt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, UK; Oxford Centre for Functional MRI of the Brain, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK.
| |
Collapse
|
24
|
Boto E, Bowtell R, Krüger P, Fromhold TM, Morris PG, Meyer SS, Barnes GR, Brookes MJ. On the Potential of a New Generation of Magnetometers for MEG: A Beamformer Simulation Study. PLoS One 2016; 11:e0157655. [PMID: 27564416 PMCID: PMC5001648 DOI: 10.1371/journal.pone.0157655] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 06/02/2016] [Indexed: 11/19/2022] Open
Abstract
Magnetoencephalography (MEG) is a sophisticated tool which yields rich information on the spatial, spectral and temporal signatures of human brain function. Despite unique potential, MEG is limited by a low signal-to-noise ratio (SNR) which is caused by both the inherently small magnetic fields generated by the brain, and the scalp-to-sensor distance. The latter is limited in current systems due to a requirement for pickup coils to be cryogenically cooled. Recent work suggests that optically-pumped magnetometers (OPMs) might be a viable alternative to superconducting detectors for MEG measurement. They have the advantage that sensors can be brought to within ~4 mm of the scalp, thus offering increased sensitivity. Here, using simulations, we quantify the advantages of hypothetical OPM systems in terms of sensitivity, reconstruction accuracy and spatial resolution. Our results show that a multi-channel whole-head OPM system offers (on average) a fivefold improvement in sensitivity for an adult brain, as well as clear improvements in reconstruction accuracy and spatial resolution. However, we also show that such improvements depend critically on accurate forward models; indeed, the reconstruction accuracy of our simulated OPM system only outperformed that of a simulated superconducting system in cases where forward field error was less than 5%. Overall, our results imply that the realisation of a viable whole-head multi-channel OPM system could generate a step change in the utility of MEG as a means to assess brain electrophysiological activity in health and disease. However in practice, this will require both improved hardware and modelling algorithms.
Collapse
Affiliation(s)
- Elena Boto
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
| | - Richard Bowtell
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
| | - Peter Krüger
- Midlands Ultracold Atom Research Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
| | - T. Mark Fromhold
- Midlands Ultracold Atom Research Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
| | - Peter G. Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
| | - Sofie S. Meyer
- Wellcome Trust Centre for Neuroimaging, University College London, 12 Queen Square, WC1N 3BG, London, United Kingdom
| | - Gareth R. Barnes
- Wellcome Trust Centre for Neuroimaging, University College London, 12 Queen Square, WC1N 3BG, London, United Kingdom
| | - Matthew J. Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, NG7 2RD, Nottingham, United Kingdom
- * E-mail:
| |
Collapse
|
25
|
Brookes MJ, Tewarie PK, Hunt BAE, Robson SE, Gascoyne LE, Liddle EB, Liddle PF, Morris PG. A multi-layer network approach to MEG connectivity analysis. Neuroimage 2016; 132:425-438. [PMID: 26908313 PMCID: PMC4862958 DOI: 10.1016/j.neuroimage.2016.02.045] [Citation(s) in RCA: 167] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 02/05/2016] [Accepted: 02/15/2016] [Indexed: 01/09/2023] Open
Abstract
Recent years have shown the critical importance of inter-regional neural network connectivity in supporting healthy brain function. Such connectivity is measurable using neuroimaging techniques such as MEG, however the richness of the electrophysiological signal makes gaining a complete picture challenging. Specifically, connectivity can be calculated as statistical interdependencies between neural oscillations within a large range of different frequency bands. Further, connectivity can be computed between frequency bands. This pan-spectral network hierarchy likely helps to mediate simultaneous formation of multiple brain networks, which support ongoing task demand. However, to date it has been largely overlooked, with many electrophysiological functional connectivity studies treating individual frequency bands in isolation. Here, we combine oscillatory envelope based functional connectivity metrics with a multi-layer network framework in order to derive a more complete picture of connectivity within and between frequencies. We test this methodology using MEG data recorded during a visuomotor task, highlighting simultaneous and transient formation of motor networks in the beta band, visual networks in the gamma band and a beta to gamma interaction. Having tested our method, we use it to demonstrate differences in occipital alpha band connectivity in patients with schizophrenia compared to healthy controls. We further show that these connectivity differences are predictive of the severity of persistent symptoms of the disease, highlighting their clinical relevance. Our findings demonstrate the unique potential of MEG to characterise neural network formation and dissolution. Further, we add weight to the argument that dysconnectivity is a core feature of the neuropathology underlying schizophrenia.
Collapse
Affiliation(s)
- Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.
| | - Prejaas K Tewarie
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Benjamin A E Hunt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Sian E Robson
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Lauren E Gascoyne
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Elizabeth B Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, United Kingdom
| | - Peter F Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| |
Collapse
|
26
|
Fry A, Mullinger KJ, O'Neill GC, Barratt EL, Morris PG, Bauer M, Folland JP, Brookes MJ. Modulation of post-movement beta rebound by contraction force and rate of force development. Hum Brain Mapp 2016; 37:2493-511. [PMID: 27061243 PMCID: PMC4982082 DOI: 10.1002/hbm.23189] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 02/12/2016] [Accepted: 03/09/2016] [Indexed: 11/30/2022] Open
Abstract
Movement induced modulation of the beta rhythm is one of the most robust neural oscillatory phenomena in the brain. In the preparation and execution phases of movement, a loss in beta amplitude is observed [movement related beta decrease (MRBD)]. This is followed by a rebound above baseline on movement cessation [post movement beta rebound (PMBR)]. These effects have been measured widely, and recent work suggests that they may have significant importance. Specifically, they have potential to form the basis of biomarkers for disease, and have been used in neuroscience applications ranging from brain computer interfaces to markers of neural plasticity. However, despite the robust nature of both MRBD and PMBR, the phenomena themselves are poorly understood. In this study, we characterise MRBD and PMBR during a carefully controlled isometric wrist flexion paradigm, isolating two fundamental movement parameters; force output, and the rate of force development (RFD). Our results show that neither altered force output nor RFD has a significant effect on MRBD. In contrast, PMBR was altered by both parameters. Higher force output results in greater PMBR amplitude, and greater RFD results in a PMBR which is higher in amplitude and shorter in duration. These findings demonstrate that careful control of movement parameters can systematically change PMBR. Further, for temporally protracted movements, the PMBR can be over 7 s in duration. This means accurate control of movement and judicious selection of paradigm parameters are critical in future clinical and basic neuroscientific studies of sensorimotor beta oscillations. Hum Brain Mapp 37:2493–2511, 2016. © 2016 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc
Collapse
Affiliation(s)
- Adam Fry
- School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, LE11 3TU, United Kingdom
| | - Karen J Mullinger
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.,Birmingham University Imaging Centre, School of Psychology, University of Birmingham, Birmingham, B15 2TT, United Kingdom
| | - George C O'Neill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Eleanor L Barratt
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Markus Bauer
- School of Psychology, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| | - Jonathan P Folland
- School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, LE11 3TU, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom
| |
Collapse
|
27
|
Liddle EB, Price D, Palaniyappan L, Brookes MJ, Robson SE, Hall EL, Morris PG, Liddle PF. Abnormal salience signaling in schizophrenia: The role of integrative beta oscillations. Hum Brain Mapp 2016; 37:1361-74. [PMID: 26853904 PMCID: PMC4790909 DOI: 10.1002/hbm.23107] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Revised: 12/11/2015] [Accepted: 12/19/2015] [Indexed: 01/24/2023] Open
Abstract
Aberrant salience attribution and cerebral dysconnectivity both have strong evidential support as core dysfunctions in schizophrenia. Aberrant salience arising from an excess of dopamine activity has been implicated in delusions and hallucinations, exaggerating the significance of everyday occurrences and thus leading to perceptual distortions and delusional causal inferences. Meanwhile, abnormalities in key nodes of a salience brain network have been implicated in other characteristic symptoms, including the disorganization and impoverishment of mental activity. A substantial body of literature reports disruption to brain network connectivity in schizophrenia. Electrical oscillations likely play a key role in the coordination of brain activity at spatially remote sites, and evidence implicates beta band oscillations in long‐range integrative processes. We used magnetoencephalography and a task designed to disambiguate responses to relevant from irrelevant stimuli to investigate beta oscillations in nodes of a network implicated in salience detection and previously shown to be structurally and functionally abnormal in schizophrenia. Healthy participants, as expected, produced an enhanced beta synchronization to behaviorally relevant, as compared to irrelevant, stimuli, while patients with schizophrenia showed the reverse pattern: a greater beta synchronization in response to irrelevant than to relevant stimuli. These findings not only support both the aberrant salience and disconnectivity hypotheses, but indicate a common mechanism that allows us to integrate them into a single framework for understanding schizophrenia in terms of disrupted recruitment of contextually appropriate brain networks. Hum Brain Mapp 37:1361‐1374, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Elizabeth B Liddle
- Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Darren Price
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom
| | - Lena Palaniyappan
- Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom
| | - Siân E Robson
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom
| | - Emma L Hall
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, United Kingdom
| | - Peter F Liddle
- Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom
| |
Collapse
|
28
|
Tewarie P, Bright MG, Hillebrand A, Robson SE, Gascoyne LE, Morris PG, Meier J, Van Mieghem P, Brookes MJ. Predicting haemodynamic networks using electrophysiology: The role of non-linear and cross-frequency interactions. Neuroimage 2016; 130:273-292. [PMID: 26827811 PMCID: PMC4819720 DOI: 10.1016/j.neuroimage.2016.01.053] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Revised: 12/23/2015] [Accepted: 01/24/2016] [Indexed: 11/21/2022] Open
Abstract
Understanding the electrophysiological basis of resting state networks (RSNs) in the human brain is a critical step towards elucidating how inter-areal connectivity supports healthy brain function. In recent years, the relationship between RSNs (typically measured using haemodynamic signals) and electrophysiology has been explored using functional Magnetic Resonance Imaging (fMRI) and magnetoencephalography (MEG). Significant progress has been made, with similar spatial structure observable in both modalities. However, there is a pressing need to understand this relationship beyond simple visual similarity of RSN patterns. Here, we introduce a mathematical model to predict fMRI-based RSNs using MEG. Our unique model, based upon a multivariate Taylor series, incorporates both phase and amplitude based MEG connectivity metrics, as well as linear and non-linear interactions within and between neural oscillations measured in multiple frequency bands. We show that including non-linear interactions, multiple frequency bands and cross-frequency terms significantly improves fMRI network prediction. This shows that fMRI connectivity is not only the result of direct electrophysiological connections, but is also driven by the overlap of connectivity profiles between separate regions. Our results indicate that a complete understanding of the electrophysiological basis of RSNs goes beyond simple frequency-specific analysis, and further exploration of non-linear and cross-frequency interactions will shed new light on distributed network connectivity, and its perturbation in pathology. We introduce a mathematical model to predict fMRI-based RSNs using MEG. Our model is based on a multi-variate Taylor series expansion. The electrophysiological basis of RSNs goes beyond frequency-band specific analysis. RSNs result 1) from multiple frequency bands and cross-frequency coupling. RSNs result 2) from direct and shared electrophysiological connectivity.
Collapse
Affiliation(s)
- P Tewarie
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK.
| | - M G Bright
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - A Hillebrand
- Department of Clinical Neurophysiology and MEG Center, VU University Medical Centre, Amsterdam, The Netherlands
| | - S E Robson
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - L E Gascoyne
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - P G Morris
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - J Meier
- Delft University of Technology, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft, The Netherlands
| | - P Van Mieghem
- Delft University of Technology, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft, The Netherlands
| | - M J Brookes
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| |
Collapse
|
29
|
Wild AR, Bollands M, Morris PG, Jones S. Mechanisms regulating spill-over of synaptic glutamate to extrasynaptic NMDA receptors in mouse substantia nigra dopaminergic neurons. Eur J Neurosci 2015; 42:2633-43. [PMID: 26370007 PMCID: PMC4832385 DOI: 10.1111/ejn.13075] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Revised: 08/31/2015] [Accepted: 09/08/2015] [Indexed: 02/02/2023]
Abstract
N‐Methyl‐d‐aspartate glutamate receptors (NMDARs) contribute to neural development, plasticity and survival, but they are also linked with neurodegeneration. NMDARs at synapses are activated by coincident glutamate release and depolarization. NMDARs distal to synapses can sometimes be recruited by ‘spill‐over’ of glutamate during high‐frequency synaptic stimulation or when glutamate uptake is compromised, and this influences the shape of NMDAR‐mediated postsynaptic responses. In substantia nigra dopamine neurons, activation of NMDARs beyond the synapse during different frequencies of presynaptic stimulation has not been explored, even though excitatory afferents from the subthalamic nucleus show a range of firing frequencies, and these frequencies change in human and experimental Parkinson's disease. This study reports that high‐frequency stimulation (80 Hz/200 ms) evoked NMDAR‐excitatory postsynaptic currents (EPSCs) that were larger and longer lasting than those evoked by single stimuli at low frequency (0.1 Hz). MK‐801, which irreversibly blocked NMDAR‐EPSCs activated during 0.1‐Hz stimulation, left a proportion of NMDAR‐EPSCs that could be activated by 80‐Hz stimulation and that may represent activity of NMDARs distal to synapses. TBOA, which blocks glutamate transporters, significantly increased NMDAR‐EPSCs in response to 80‐Hz stimulation, particularly when metabotropic glutamate receptors (mGluRs) were also blocked, indicating that recruitment of NMDARs distal to synapses is regulated by glutamate transporters and mGluRs. These regulatory mechanisms may be essential in the substantia nigra for restricting glutamate diffusion from synaptic sites and keeping NMDAR‐EPSCs in dopamine neurons relatively small and fast. Failure of glutamate transporters may contribute to the declining health of dopamine neurons during pathological conditions.
Collapse
Affiliation(s)
- A R Wild
- Department of Physiology, Development & Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK
| | - M Bollands
- Department of Physiology, Development & Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK
| | - P G Morris
- Department of Physiology, Development & Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK
| | - S Jones
- Department of Physiology, Development & Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, UK
| |
Collapse
|
30
|
Robson SE, Brookes MJ, Hall EL, Palaniyappan L, Kumar J, Skelton M, Christodoulou NG, Qureshi A, Jan F, Katshu MZ, Liddle EB, Liddle PF, Morris PG. Abnormal visuomotor processing in schizophrenia. Neuroimage Clin 2015; 12:869-878. [PMID: 27872809 PMCID: PMC5107643 DOI: 10.1016/j.nicl.2015.08.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Revised: 08/11/2015] [Accepted: 08/13/2015] [Indexed: 11/30/2022]
Abstract
Subtle disturbances of visual and motor function are known features of schizophrenia and can greatly impact quality of life; however, few studies investigate these abnormalities using simple visuomotor stimuli. In healthy people, electrophysiological data show that beta band oscillations in sensorimotor cortex decrease during movement execution (event-related beta desynchronisation (ERBD)), then increase above baseline for a short time after the movement (post-movement beta rebound (PMBR)); whilst in visual cortex, gamma oscillations are increased throughout stimulus presentation. In this study, we used a self-paced visuomotor paradigm and magnetoencephalography (MEG) to contrast these responses in patients with schizophrenia and control volunteers. We found significant reductions in the peak-to-peak change in amplitude from ERBD to PMBR in schizophrenia compared with controls. This effect was strongest in patients who made fewer movements, whereas beta was not modulated by movement in controls. There was no significant difference in the amplitude of visual gamma between patients and controls. These data demonstrate that clear abnormalities in basic sensorimotor processing in schizophrenia can be observed using a very simple MEG paradigm. Visual and motor deficits in schizophrenia are rarely investigated. We use MEG to non-invasively assess the neural basis of these deficits. Patients showed abnormalities in neuronal oscillations in motor cortex. Beta band power, reflecting cortical inhibition, was reduced after movements. Increased movement frequency may be a behavioural compensation for this reduction.
Collapse
Affiliation(s)
- Siân E Robson
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
| | - Emma L Hall
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
| | - Lena Palaniyappan
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Jyothika Kumar
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Michael Skelton
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Nikolaos G Christodoulou
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Ayaz Qureshi
- Kevin White Unit, Smithdown Health Park, Smithdown Road, Liverpool L15 2HE, UK
| | - Fiesal Jan
- Herschel Prins Centre, Glenfield Hospital, Leicestershire Partnership NHS Trust, Groby Road, Leicester LE3 9QP, UK
| | - Mohammad Z Katshu
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Elizabeth B Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Peter F Liddle
- Centre for Translational Neuroimaging in Mental Health, Institute of Mental Health, School of Medicine, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham NG7 2TU, UK
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
| |
Collapse
|
31
|
O'Neill GC, Bauer M, Woolrich MW, Morris PG, Barnes GR, Brookes MJ. Dynamic recruitment of resting state sub-networks. Neuroimage 2015; 115:85-95. [PMID: 25899137 PMCID: PMC4573462 DOI: 10.1016/j.neuroimage.2015.04.030] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 03/19/2015] [Accepted: 04/11/2015] [Indexed: 11/19/2022] Open
Abstract
Resting state networks (RSNs) are of fundamental importance in human systems neuroscience with evidence suggesting that they are integral to healthy brain function and perturbed in pathology. Despite rapid progress in this area, the temporal dynamics governing the functional connectivities that underlie RSN structure remain poorly understood. Here, we present a framework to help further our understanding of RSN dynamics. We describe a methodology which exploits the direct nature and high temporal resolution of magnetoencephalography (MEG). This technique, which builds on previous work, extends from solving fundamental confounds in MEG (source leakage) to multivariate modelling of transient connectivity. The resulting processing pipeline facilitates direct (electrophysiological) measurement of dynamic functional networks. Our results show that, when functional connectivity is assessed in small time windows, the canonical sensorimotor network can be decomposed into a number of transiently synchronising sub-networks, recruitment of which depends on current mental state. These rapidly changing sub-networks are spatially focal with, for example, bilateral primary sensory and motor areas resolved into two separate sub-networks. The likely interpretation is that the larger canonical sensorimotor network most often seen in neuroimaging studies reflects only a temporal aggregate of these transient sub-networks. Our approach opens new frontiers to study RSN dynamics, showing that MEG is capable of revealing the spatial, temporal and spectral signature of the human connectome in health and disease. The sensorimotor network consists of a series of transiently synchronising subnetworks. These subnetworks are robust across multiple tasks. The occurrence of these subnetworks is modulated by the current mental state.
Collapse
Affiliation(s)
- George C O'Neill
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Markus Bauer
- School of Psychology, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom; fMRIB Centre, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
| | - Peter G Morris
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom
| | - Gareth R Barnes
- Wellcome Trust Centre for Neuroimaging, University College London, 12 Queen Square, London WC1N 3BG, United Kingdom
| | - Matthew J Brookes
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom.
| |
Collapse
|
32
|
Bawden SJ, Stephenson MC, Ciampi E, Hunter K, Marciani L, Macdonald IA, Aithal GP, Morris PG, Gowland PA. Investigating the effects of an oral fructose challenge on hepatic ATP reserves in healthy volunteers: A (31)P MRS study. Clin Nutr 2015; 35:645-9. [PMID: 25935852 DOI: 10.1016/j.clnu.2015.04.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Revised: 03/02/2015] [Accepted: 04/03/2015] [Indexed: 01/09/2023]
Abstract
BACKGROUND Impaired homeostasis of hepatic ATP has been associated with NAFLD. An intravenous fructose infusion has been shown to be an effective challenge to monitor the depletion and subsequent recovery of hepatic ATP reserves using (31)P MRS. AIMS The purpose of this study was to evaluate the effects of an oral rather than intravenous fructose challenge on hepatic ATP reserves in healthy subjects. METHODS Self-reported healthy males were recruited. Following an overnight fast, baseline liver glycogen and lipid levels were measured using Magnetic Resonance Spectroscopy (MRS). Immediately after consuming a 500 ml 75 g fructose drink (1275 kJ) subjects were scanned continuously for 90 min to acquire dynamic (31)P MRS measurements of liver ATP reserves. RESULTS A significant effect on ATP reserves was observed across the time course (P < 0.05). Mean ATP levels reached a minimum at 50 min which was markedly lower than baseline (80 ± 17% baseline, P < 0.05). Subsequently, mean values tended to rise but did not reach statistical significance above minimum. The time to minimum ATP levels across subjects was negatively correlated with BMI (R(2) = 0.74, P < 0.005). Rates of ATP recovery were not significantly correlated with BMI or liver fat levels, but were negatively correlated with baseline glycogen levels (R(2) = 0.7, P < 0.05). CONCLUSIONS Depletion of ATP reserves can be measured non-invasively following an oral fructose challenge using (31)P MRS. BMI is the best predictor of postprandial ATP homeostasis following fructose consumption.
Collapse
Affiliation(s)
- S J Bawden
- Sir Peter Manfield Imaging Centre, University of Nottingham, Nottingham, UK.
| | - M C Stephenson
- Sir Peter Manfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - E Ciampi
- Unilever Discover, Unilever, Colworth, UK
| | - K Hunter
- Unilever Discover, Unilever, Colworth, UK
| | - L Marciani
- NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
| | - I A Macdonald
- School of Life Sciences, University of Nottingham, Nottingham, UK
| | - G P Aithal
- NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
| | - P G Morris
- Sir Peter Manfield Imaging Centre, University of Nottingham, Nottingham, UK
| | - P A Gowland
- Sir Peter Manfield Imaging Centre, University of Nottingham, Nottingham, UK
| |
Collapse
|
33
|
Hall EL, Robson SE, Morris PG, Brookes MJ. The relationship between MEG and fMRI. Neuroimage 2014; 102 Pt 1:80-91. [DOI: 10.1016/j.neuroimage.2013.11.005] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Revised: 09/12/2013] [Accepted: 11/04/2013] [Indexed: 10/26/2022] Open
|
34
|
Draper A, Stephenson MC, Jackson GM, Pépés S, Morgan PS, Morris PG, Jackson SR. Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol 2014; 24:2343-7. [PMID: 25264251 PMCID: PMC4188813 DOI: 10.1016/j.cub.2014.08.038] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 08/05/2014] [Accepted: 08/18/2014] [Indexed: 11/27/2022]
Abstract
Tourette syndrome (TS) is a developmental neurological disorder characterized by vocal and motor tics and associated with cortical-striatal-thalamic-cortical circuit dysfunction, hyperexcitability within cortical motor areas, and altered intracortical inhibition. TS often follows a developmental time course in which tics become increasingly more controlled during adolescence in many individuals, who exhibit enhanced control over their volitional movements. Importantly, control over motor outputs appears to be brought about by a reduction in the gain of motor excitability. Here we present a neurochemical basis for a localized gain control mechanism. We used ultra-high-field (7 T) magnetic resonance spectroscopy to investigate in vivo concentrations of γ-aminobutyric acid (GABA) within primary and secondary motor areas of individuals with TS. We demonstrate that GABA concentrations within the supplementary motor area (SMA)--a region strongly associated with the genesis of motor tics in TS--are paradoxically elevated in individuals with TS and inversely related to fMRI blood oxygen level-dependent activation. By contrast, GABA concentrations in control sites do not differ from those of a matched control group. Importantly, we also show that GABA concentrations within the SMA are inversely correlated with cortical excitability in primary motor cortex and are predicted by motor tic severity and white-matter microstructure (FA) within a region of the corpus callosum that projects to the SMA within each hemisphere. Based upon these findings, we propose that extrasynaptic GABA contributes to a form of control, based upon localized tonic inhibition within the SMA, that may lead to the suppression of tics.
Collapse
Affiliation(s)
- Amelia Draper
- School of Psychology, University of Nottingham, Nottingham NG7 2RD, UK
| | - Mary C Stephenson
- Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, UK
| | - Georgina M Jackson
- Division of Psychiatry and Applied Psychology, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham NG7 2TU, UK
| | - Sophia Pépés
- School of Psychology, University of Nottingham, Nottingham NG7 2RD, UK
| | - Paul S Morgan
- Medical Physics and Clinical Engineering, Queen's Medical Centre, Nottingham NG7 2RD, UK
| | - Peter G Morris
- Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, UK
| | - Stephen R Jackson
- School of Psychology, University of Nottingham, Nottingham NG7 2RD, UK.
| |
Collapse
|
35
|
Kim S, Stephenson MC, Morris PG, Jackson SR. tDCS-induced alterations in GABA concentration within primary motor cortex predict motor learning and motor memory: a 7 T magnetic resonance spectroscopy study. Neuroimage 2014; 99:237-43. [PMID: 24904994 PMCID: PMC4121086 DOI: 10.1016/j.neuroimage.2014.05.070] [Citation(s) in RCA: 155] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 05/19/2014] [Accepted: 05/27/2014] [Indexed: 11/10/2022] Open
Abstract
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that alters cortical excitability in a polarity specific manner and has been shown to influence learning and memory. tDCS may have both on-line and after-effects on learning and memory, and the latter are thought to be based upon tDCS-induced alterations in neurochemistry and synaptic function. We used ultra-high-field (7 T) magnetic resonance spectroscopy (MRS), together with a robotic force adaptation and de-adaptation task, to investigate whether tDCS-induced alterations in GABA and Glutamate within motor cortex predict motor learning and memory. Note that adaptation to a robot-induced force field has long been considered to be a form of model-based learning that is closely associated with the computation and ‘supervised’ learning of internal ‘forward’ models within the cerebellum. Importantly, previous studies have shown that on-line tDCS to the cerebellum, but not to motor cortex, enhances model-based motor learning. Here we demonstrate that anodal tDCS delivered to the hand area of the left primary motor cortex induces a significant reduction in GABA concentration. This effect was specific to GABA, localised to the left motor cortex, and was polarity specific insofar as it was not observed following either cathodal or sham stimulation. Importantly, we show that the magnitude of tDCS-induced alterations in GABA concentration within motor cortex predicts individual differences in both motor learning and motor memory on the robotic force adaptation and de-adaptation task. Ultra-high-field (7 T) magnetic resonance spectroscopy study of the effects of tDCS. Anodal tDCS leads to a polarity and site specific reduction in MRS-GABA. tDCS-induced changes in MRS-GABA in M1 predict model-based motor learning/memory.
Collapse
Affiliation(s)
- Soyoung Kim
- Brain and Body Centre, School of Psychology, University of Nottingham, UK
| | - Mary C Stephenson
- Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, UK
| | - Peter G Morris
- Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, UK
| | - Stephen R Jackson
- Brain and Body Centre, School of Psychology, University of Nottingham, UK.
| |
Collapse
|
36
|
Brookes MJ, O'Neill GC, Hall EL, Woolrich MW, Baker A, Palazzo Corner S, Robson SE, Morris PG, Barnes GR. Measuring temporal, spectral and spatial changes in electrophysiological brain network connectivity. Neuroimage 2014; 91:282-99. [PMID: 24418505 DOI: 10.1016/j.neuroimage.2013.12.066] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Revised: 12/27/2013] [Accepted: 12/31/2013] [Indexed: 11/16/2022] Open
Affiliation(s)
- Matthew J Brookes
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK.
| | - George C O'Neill
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Emma L Hall
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Mark W Woolrich
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, UK; Oxford Centre for Functional MRI of the Brain, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Adam Baker
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, UK
| | - Sofia Palazzo Corner
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Siân E Robson
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Peter G Morris
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
| | - Gareth R Barnes
- Wellcome Trust Centre for Neuroimaging, University College London, London, UK
| |
Collapse
|
37
|
Cadoo KA, Morris PG, Lake DE, D'Andrea GM, Dickler MN, Gilewski TA, Dang CT, McArthur HL, Bromberg JF, Goldfarb SB, Modi S, Robson ME, Seidman AD, Sklarin NT, Norton L, Hudis CA, Fornier MN. Abstract P2-16-12: An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-16-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The role of dasatinib, an oral SRC inhibitor is being explored for the treatment of metastatic breast cancer. In a phase I study, we previously established that the combination of dasatinib and weekly paclitaxel was feasible. The activity of this combination is currently being explored in an ongoing phase II trial. Since Src kinase has a major role in osteoclast function and dasatinib has established anabolic and anti-resorptive effects in bone in vitro, we hypothesized that patients receiving this combination would have good control of osseous metastases and primarily develop progression of disease in sites other than bone.
Patients and methods: Patients were included in this analysis if they participated in the phase I or II metastatic breast cancer studies and received dasatinib at or above the recommended phase II dose of 120mg with paclitaxel (80mg/m2 day 1 and 8 of each 21day cycle). Patients who discontinued therapy for reasons other than progression were excluded. Per protocol, patients were required to discontinue bisphosphonates or other bone modulating agents for the first 8 weeks of study due to the potential for hypocalcaemia. Thereafter, they were permitted to receive these agents at the discretion of their treating physician. Patients provided serum samples for correlative studies. Assessment of N-telopeptide of type 1 collagen (NTX), a product of mature bone collagen that reflects bone specific resorption, is planned.
Results: The median age of the 24 patients who met criteria for analysis was 50y (37 - 66y). Of these, 15 (63%) had ER+ disease, and 24 (100%) were negative for human epidermal growth factor receptor (HER2). At study entry, 17 (71%) patients had bone involvement. Following the initial eight week moratorium, 7 (29%) patients received a bisphosphonate or rank ligand inhibitor during treatment with dasatinib + paclitaxel. Patients received a median 2 months (range 1-23) of dasatinib + paclitaxel therapy. To date, 3 (13%) continue on therapy, and 21 (88%) have had progression of disease. Among patients who progressed, 18 (86%) have progressed in visceral sites and only 3 (14%) progressed in bone. Analyses of serum NTX levels are ongoing and will be compared by site of progression.
Conclusion: The potential role of serum NTX as a predictive biomarker of benefit from dasatinib and paclitaxel is being explored and updated results will be presented.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-12.
Collapse
Affiliation(s)
- KA Cadoo
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - PG Morris
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - DE Lake
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - GM D'Andrea
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Dickler
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - TA Gilewski
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CT Dang
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - HL McArthur
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - JF Bromberg
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - SB Goldfarb
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Modi
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - ME Robson
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - AD Seidman
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - NT Sklarin
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - CA Hudis
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - MN Fornier
- Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
38
|
Gucalp A, Morris PG, Zhou XK, Giri DD, Iyengar NM, Heckman-Stoddard BM, Dunn B, Garber JE, Crew KD, Hershman DL, Nangia JR, Cook ED, Brown PH, Dannenberg AJ, Hudis CA. Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-3-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The development of effective chemopreventive strategies to reduce the risk of TNBC, is a critical unmet need. Obesity is associated with a chronic inflammatory condition in the white adipose tissue of the breast, characterized microscopically by crown-like structures of the breast (CLS-B). The presence and extent of these lesions is associated with a series of proinflammatory mediators, including tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β) and aromatase. Importantly these proinflammatory mediators are known to be involved in breast carcinogenesis. In translational studies to date, the strongest correlations have been seen between CLS-B and TNF-α. Therefore, we aim to evaluate whether treatment with a dietary supplement, DHA, an omega-3 fatty acid, with potent effects on TNF-α, can decrease obesity-related breast inflammation in women.
Trial design: This is a randomized phase II placebo-controlled, double-blinded study of DHA in overweight/obese patients (pts), defined as body mass index (BMI) ≥25 with a history of TNBC. Pts will receive DHA or placebo twice daily for 24 weeks and will undergo core biopsies from normal (non-irradiated contralateral) breast tissue before and after the treatment to determine whether DHA can decrease obesity-related breast inflammation.
Eligibility: Inclusion criteria: 1) Age ≥ 18. 2) BMI ≥ 25. 3) Completed treatment for stage I-III TNBC ≥ 6 months prior. 4) No clinical evidence of disease. 5) Adequate accessible breast tissue for pre- and post- treatment biopsy, consisting of one breast unaffected by invasive cancer, which has not been radiated or surgically augmented. 6) Adequate organ and bone marrow function. 7) ECOG status ≤2. Exclusion criteria: 1) DHA supplementation. 2) Aspirin/NSAID use in the month preceding and during the trial. 3) Therapeutic anticoagulation. 4) Regular use of statins, steroids, or immunomodulators.
Specific aims: The primary objective is to determine whether treatment with DHA for 24 weeks at 1,000 mg twice daily as compared to placebo reduces normal breast tissue levels of TNF-α in overweight/obese pts with a history of TNBC. The secondary objective is to evaluate the effect of DHA on the change from baseline in levels of the following tissue biomarkers: COX-2, IL-1β, aromatase, and CLS-B. Exploratory endpoints include assessment of age as a predictor of CLS-B and inflammatory biomarkers and the evaluation of red blood cell fatty acid levels as a surrogate of DHA compliance.
Statistical methods: Percent change in TNF-α mRNA levels in normal breast tissue between DHA and placebo arm will be compared using two-sample t-test. If normality assumptions are violated, a two-sample Wilcoxon rank-sum test will be used. With 30 subjects in each arm, we will have 80% power to detect effect size as small as 0.74 at 0.05 significance level using a two-sided, two-sample, Student t-test.
Accrual: A total of 60 evaluable pts will be enrolled. Assuming a 10% dropout rate and 10% non-evaluable rate, up to 76 participants will be randomized in this study. This trial is currently enrolling pts.
Contact information: For more information on this trial, please visit clinicaltrials.gov (NCT01849250) or contact Ayca Gucalp MD (gucalpa@mskcc.org).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-3-01.
Collapse
Affiliation(s)
- A Gucalp
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - PG Morris
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - XK Zhou
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - DD Giri
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - NM Iyengar
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - BM Heckman-Stoddard
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - B Dunn
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - JE Garber
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - KD Crew
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - DL Hershman
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - JR Nangia
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - ED Cook
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - PH Brown
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - AJ Dannenberg
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD
| |
Collapse
|
39
|
Iyengar NM, Morris PG, Zhou XK, Giri DD, Harbus MD, Falcone DJ, Gucalp A, Morrow M, Hudis CA, Dannenberg AJ. Abstract P1-06-03: Validating the link between obesity and breast inflammation in women with breast cancer (BC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-06-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In post-menopausal women, obesity is a risk factor for the development of BC that expresses the estrogen and progesterone receptors (ER/PR). In mouse models of obesity, we previously described crown-like structures (CLS), consisting of macrophages surrounding dead adipocytes in white adipose tissue (WAT) of the mammary gland, which were associated with increased levels of proinflammatory mediators known to be involved in carcinogenesis. We translated these findings to women (n = 30), and provided the first evidence of CLS in the human breast (CLS-B). The presence and severity of CLS-B (CLS-B index) correlated with elevated body mass index (BMI), increased adipocyte size, activation of NF-κB, and increased levels of proinflammatory mediators (TNF-α, IL-1β, COX-2 and PGE2) and aromatase. We expanded our population to prospectively validate these preliminary findings.
Methods: We prospectively collected WAT from women undergoing breast and reconstructive surgery. WAT was subjected to immunohistochemistry for CD68, a macrophage marker, to detect CLS-B by light microscopy. Adipocyte diameter was measured on photomicrographs using the Canvas 11 Software. Endpoints were 1) CLS-B presence/absence and 2) CLS-B index (proportion of slides with CLS-B). Associations between CLS-B and clinicopathologic features were analyzed using logistic regression and Fisher's exact test.
Results: From 04/2010-02/2012, WAT (100 mastectomy and 5 abdominal reconstructions) was obtained from 101 women; median age 49 (range 26-80). CLS-B were found in 54 (53%) patients (pts). CLS-B were seen in 9/37 (24%) normal weight pts (BMI <25), 23/39 (59%) overweight pts (BMI 25-29.9), and 22/25 (88%) obese pts (BMI ≥30). Pts with CLS-B had significantly larger average adipocyte diameter (106.5 +/- 11.5 microns) compared to those without CLS-B (91.5 +/- 16.1 microns; p<0.001). Consistently, CLS-B index correlated with BMI (p<0.001) and adipocyte size (p<0.001). Breast inflammation was seen in pts with all tumor phenotypes: CLS-B were seen in 24/41 (59%) pts with ER/PR+, HER2- tumors; 7/16 (44%) pts with HER2+ tumors; and 3/10 (30%) pts with ER/PR/HER2- tumors. A higher CLS-B index was seen in WAT from ER+ tumors, but this was not statistically significant (p = 0.08). Regular use of nonsteroidal antiinflammatory drugs was protective against CLS-B (p = 0.17 for association with CLS-B, and p = 0.04 for association with CLS-B index in multivariable analyses). Among 25 pts with bilateral breast WAT, concordant CLS-B findings (+/-) were found in 20 (80%) pts. Among pts with paired breast and abdominal WAT, concordant findings were seen in 4/5 (80%) pts.
Conclusions: Findings from this prospective study, the largest reported to date, extend our previous observation that CLS-B are associated with BMI and adipocyte size. These results provide a plausible pathophysiological link between obesity and BC. Breast inflammation occurs in association with all BC phenotypes. Preliminary data suggest concordance between breasts and between abdominal and breast WAT. Hence, abdominal WAT may prove useful as a surrogate for breast WAT; biopsies of abdominal subcutaneous WAT are more easily done, which could prove useful in developing interventions to attenuate WAT inflammation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-06-03.
Collapse
Affiliation(s)
- NM Iyengar
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - PG Morris
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - XK Zhou
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - DD Giri
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - MD Harbus
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - DJ Falcone
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - A Gucalp
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - M Morrow
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| | - AJ Dannenberg
- Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Rockefeller University, New York, NY
| |
Collapse
|
40
|
Mansi L, Evangelista L, Morris PG. The future of imaging for breast cancer recurrence. Q J Nucl Med Mol Imaging 2013; 57:381-382. [PMID: 24322794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- L Mansi
- Nuclear Medicine Unit Department of Clinical and Experimental Internistic ''F. Magrassi, A. Lanzara'' - Seconda Università di Napoli Naples, Italy -
| | | | | |
Collapse
|
41
|
Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging 2013; 57:312-321. [PMID: 24322788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Breast cancer is comprised of a number of complex and heterogeneous subtypes with differing clinical behavior and outcomes. In recent years, significant advances have been made in discerning the molecular drivers of this disease, and characterizing distinct subtypes of breast cancer based on gene expression profiles. These advances have begun to translate into greater individualization of treatment for patients. Although these advances have shaped our understanding of the underlying biology of breast cancer, most clinical decisions are currently based on tumor expression of the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). These biomarkers have prognostic and predictive significance in breast cancer and have important implications for tumor growth and metastatic patterns. In this review, we focus on the three broad phenotypes of breast cancer used in clinical practice; ER/PR positive, HER2 positive and triple negative breast cancer (TNBC), which is characterized by lack of expression of ER, PR and HER2. We discuss the influence of these tumor-related factors as well as histological subtype, on the potential for breast cancer recurrence and patterns of disease spread.
Collapse
Affiliation(s)
- K A Cadoo
- The Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, USA -
| | | | | |
Collapse
|
42
|
Evangelista L, Morris PG, Mansi L. How can we optimize modern imaging techniques for breast cancer, with main reference to breast recurrence? Q J Nucl Med Mol Imaging 2013; 57:309-311. [PMID: 24322787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- L Evangelista
- Radiotherapy and Nuclear Medicine Unit Veneto Institute of Oncology, Padua, Italy -
| | | | | |
Collapse
|
43
|
Stephenson MC, Leverton E, Khoo EYH, Poucher SM, Johansson L, Lockton JA, Eriksson JW, Mansell P, Morris PG, MacDonald IA. Variability in fasting lipid and glycogen contents in hepatic and skeletal muscle tissue in subjects with and without type 2 diabetes: a 1H and 13C MRS study. NMR Biomed 2013; 26:1518-1526. [PMID: 23836451 DOI: 10.1002/nbm.2985] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Revised: 04/19/2013] [Accepted: 05/14/2013] [Indexed: 06/02/2023]
Abstract
The measurement of tissue lipid and glycogen contents and the establishment of normal levels of variability are important when assessing changes caused by pathology or treatment. We measured hepatic and skeletal muscle lipid and glycogen levels using (1)H and (13)C MRS at 3 T in groups of subjects with and without type 2 diabetes. Within-visit reproducibility, due to repositioning and instrument errors was determined from repeat measurements made over 1 h. Natural variability was assessed from separate measurements made on three occasions over 1 month. Hepatic lipid content was greater in subjects with diabetes relative to healthy subjects (p = 0.03), whereas levels of hepatic and skeletal muscle glycogen, and of intra- and extra-myocellular lipid, were similar. The single-session reproducibility values (coefficient of variation, CV) for hepatic lipid content were 12% and 7% in groups of subjects with and without diabetes, respectively. The variability of hepatic lipid content over 1 month was greater than the reproducibility, with CV = 22% (p = 0.08) and CV = 44% (p = 0.004) in subjects with and without diabetes, respectively. Similarly, levels of variation in basal hepatic glycogen concentrations (subjects with diabetes, CV = 38%; healthy volunteers, CV = 35%) were significantly larger than single-session reproducibility values (CV = 17%, p = 0.02 and CV = 13%, p = 0.05, respectively), indicating substantial biological changes in basal concentrations over 1 month. There was a decreasing correlation in measurements of both hepatic lipid and glycogen content with increasing time between scans. Levels of variability in intra- and extra-myocellular lipid in the soleus muscle, and glycogen concentrations in the gastrocnemius muscle, tended to be larger than expected from single-session reproducibility, although these did not reach significance.
Collapse
Affiliation(s)
- M C Stephenson
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Six JS, Hughes-Riley T, Lilburn DML, Dorkes AC, Stupic KF, Shaw DE, Morris PG, Hall IP, Pavlovskaya GE, Meersmann T. Pulmonary MRI contrast using Surface Quadrupolar Relaxation (SQUARE) of hyperpolarized (83)Kr. Magn Reson Imaging 2013; 32:48-53. [PMID: 24144493 PMCID: PMC3898897 DOI: 10.1016/j.mri.2013.08.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 08/08/2013] [Accepted: 08/20/2013] [Indexed: 11/24/2022]
Abstract
Hyperpolarized 83Kr has previously been demonstrated to enable MRI contrast that is sensitive to the chemical composition of the surface in a porous model system. Methodological advances have lead to a substantial increase in the 83Kr hyperpolarization and the resulting signal intensity. Using the improved methodology for spin exchange optical pumping of isotopically enriched 83Kr, internal anatomical details of ex vivo rodent lung were resolved with hyperpolarized 83Kr MRI after krypton inhalation. Different 83Kr relaxation times were found between the main bronchi and the parenchymal regions in ex vivo rat lungs. The T1 weighted hyperpolarized 83Kr MRI provided a first demonstration of surface quadrupolar relaxation (SQUARE) pulmonary MRI contrast.
Collapse
Affiliation(s)
- Joseph S Six
- Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, UK; School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Hall EL, Stephenson MC, Price D, Morris PG. Methodology for improved detection of low concentration metabolites in MRS: optimised combination of signals from multi-element coil arrays. Neuroimage 2013; 86:35-42. [PMID: 23639258 DOI: 10.1016/j.neuroimage.2013.04.077] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 04/16/2013] [Accepted: 04/17/2013] [Indexed: 01/08/2023] Open
Abstract
State of the art magnetic resonance imaging (MRI) scanners are generally equipped with multi-element receive coils; 16 or 32 channel coils are common. Their development has been predominant for parallel imaging to enable faster scanning. Less consideration has been given to localized magnetic resonance spectroscopy (MRS). Multinuclear studies, for example (31)P or (13)C MRS, are often conducted with a single element coil located over the region of interest. (1)H MRS studies have generally employed the same multi-element coils used for MRI, but little consideration has been given as to how the spectroscopic data from the different channels are combined. In many cases it is simply co-added with detrimental effect on the signal to noise ratio. In this study, we derive the optimum method for combining multi-coil data, namely weighting with the ratio of signal to the square of the noise. We show that provided that the noise is uncorrelated, this is the theoretical optimal combination. The method is demonstrated for in vivo proton MRS data acquired using a 32 channel receive coil at 7T in four different brain areas; left motor and right motor, occipital cortex and medial frontal cortex.
Collapse
Affiliation(s)
- Emma L Hall
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK.
| | - Mary C Stephenson
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Darren Price
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Peter G Morris
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| |
Collapse
|
46
|
Morris PG, Lake D, McArthur HL, Gilewski T, Dang C, Chaim J, Patl S, Lim K, Norton L, Hudis CA, Fornier MN. Abstract P5-20-07: Phase II Trial of Dasatinib in Combination With Weekly Paclitaxel for Patients with Metastatic Breast Carcinoma. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Src kinase plays an important role in proliferation, survival, angiogenesis and metastasis in several malignancies including breast cancer. Therefore, inhibition of Src and other tyrosine kinases (TKs) represents a novel therapeutic approach. Dasatinib is a potent inhibitor of 5 oncogenic TKs, inhibits VEGF-stimulated proliferation, has potent bone anti-resorptive activity and selectively inhibits basal-type breast cancer growth. Preclinically, the combination of dasatinib and paclitaxel had superior antitumor activity to either agent alone. In a previous phase I study, we determined that, in combination with weekly paclitaxel, the optimum dose of dasatinib was 120mg. Of note, 4/9 (44%) patients treated at or above this dasatinib dose level had objective tumor response. We now present results from the phase II trial of this combination.
Methods: Patients with MBC, ECOG PS 0–1, normal hepatic, renal, marrow function were eligible. Patients had measurable, HER2-negative metastatic breast cancer (MBC), ≤2 prior therapies for MBC. Treatment consisted of weekly paclitaxel 80 mg/m2 IV 3/4 weeks + Dasatinib 120mg orally daily. Response was assessed by RECIST after every 8 weeks of therapy. Simon's two-stage optimal design was used to test the null hypothesis of a 15% response rate (RR) against the alternative of a 30% RR. In stage I, planned enrollment was 23 patients based on Type I and Type II errors of 10%. If 4 or more responses are observed, enrollment will be extended to 55 patients. Exploratory correlative biomarkers of clinical benefit include Src phosphorylation (p-Src) in peripheral blood mononuclear cells, plasma levels of VEGFR2 and collagen Type IV, circulating tumor cells (CTCs) and tumor gene expression profiling.
Results: 21 patients (19 females, 2 male) have enrolled; median age 48 (range 30–79). Patients received a median of 1 prior therapy for MBC (range 0–2). 6 patients are not assessable for response: 1 has received <8 weeks treatment, 5 came off study for toxicity (2 hypersensitivity reaction to paclitaxel, 1 infection, 1 diarrhea/nausea, 1 bleeding likely related to anticoagulation). Among the 15 patients assessable for response, best response to date is as follows: 2 (13%) patients partial response, 11 (73%) patients stable disease (SD) and 2 (13%) patients progression of disease. Of patients with SD, 6/11 (55%) continue on treatment after median of 2 months (range 2–10) and 5/11 (45%) patients have come off study after median of 10 months (range 3–21). Most toxicities have been hematological and low grade. Diarrhea and neuropathy have generally been low grade and no new toxicities related to the combination have occurred since expansion into the phase II. Potential biomarkers of clinical benefit including, p-Src, VEGFR2, collagen Type IV, and CTCs will be presented.
Conclusion: Data from this phase II has demonstrated preliminary evidence of activity for weekly paclitaxel and dasatinib 120mg in patients with MBC. These findings are consistent with data from this dose level in the earlier phase I study. Predictive biomarkers of clinical benefit are under investigation.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-07.
Collapse
Affiliation(s)
- PG Morris
- Memorial Sloan-Kettering Cancer Center, New York
| | - D Lake
- Memorial Sloan-Kettering Cancer Center, New York
| | - HL McArthur
- Memorial Sloan-Kettering Cancer Center, New York
| | - T Gilewski
- Memorial Sloan-Kettering Cancer Center, New York
| | - C Dang
- Memorial Sloan-Kettering Cancer Center, New York
| | - J Chaim
- Memorial Sloan-Kettering Cancer Center, New York
| | - S Patl
- Memorial Sloan-Kettering Cancer Center, New York
| | - K Lim
- Memorial Sloan-Kettering Cancer Center, New York
| | - L Norton
- Memorial Sloan-Kettering Cancer Center, New York
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center, New York
| | - MN Fornier
- Memorial Sloan-Kettering Cancer Center, New York
| |
Collapse
|
47
|
Hall EL, Woolrich MW, Thomaz CE, Morris PG, Brookes MJ. Using variance information in magnetoencephalography measures of functional connectivity. Neuroimage 2012; 67:203-12. [PMID: 23165323 DOI: 10.1016/j.neuroimage.2012.11.011] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 11/02/2012] [Accepted: 11/09/2012] [Indexed: 10/27/2022] Open
Abstract
The use of magnetoencephalography (MEG) to assess long range functional connectivity across large scale distributed brain networks is gaining popularity. Recent work has shown that electrodynamic networks can be assessed using both seed based correlation or independent component analysis (ICA) applied to MEG data and further that such metrics agree with fMRI studies. To date, techniques for MEG connectivity assessment have typically used a variance normalised approach, either through the use of Pearson correlation coefficients or via variance normalisation of envelope timecourses prior to ICA. Here, we show that the use of variance information (i.e. data that have not been variance normalised) in source space projected Hilbert envelope time series yields important spatial information, and is of significant functional relevance. Further, we show that employing this information in functional connectivity analyses improves the spatial delineation of network nodes using both seed based and ICA approaches. The use of variance is particularly important in MEG since the non-independence of source space voxels (brought about by the ill-posed MEG inverse problem) means that spurious signals can exist in areas of low signal variance. We therefore suggest that this approach be incorporated into future studies.
Collapse
Affiliation(s)
- Emma L Hall
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | | | | | | | | |
Collapse
|
48
|
Brookes MJ, Liddle EB, Hale JR, Woolrich MW, Luckhoo H, Liddle PF, Morris PG. Task induced modulation of neural oscillations in electrophysiological brain networks. Neuroimage 2012; 63:1918-30. [PMID: 22906787 DOI: 10.1016/j.neuroimage.2012.08.012] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Revised: 08/02/2012] [Accepted: 08/05/2012] [Indexed: 11/24/2022] Open
Abstract
In recent years, one of the most important findings in systems neuroscience has been the identification of large scale distributed brain networks. These networks support healthy brain function and are perturbed in a number of neurological disorders (e.g. schizophrenia). Their study is therefore an important and evolving focus for neuroscience research. The majority of network studies are conducted using functional magnetic resonance imaging (fMRI) which relies on changes in blood oxygenation induced by neural activity. However recently, a small number of studies have begun to elucidate the electrical origin of fMRI networks by searching for correlations between neural oscillatory signals from spatially separate brain areas in magnetoencephalography (MEG) data. Here we advance this research area. We introduce two methodological extensions to previous independent component analysis (ICA) approaches to MEG network characterisation: 1) we show how to derive pan-spectral networks that combine independent components computed within individual frequency bands. 2) We show how to measure the temporal evolution of each network with millisecond temporal resolution. We apply our approach to ~10h of MEG data recorded in 28 experimental sessions during 3 separate cognitive tasks showing that a number of networks could be identified and were robust across time, task, subject and recording session. Further, we show that neural oscillations in those networks are modulated by memory load, and task relevance. This study furthers recent findings on electrodynamic brain networks and paves the way for future clinical studies in patients in which abnormal connectivity is thought to underlie core symptoms.
Collapse
Affiliation(s)
- M J Brookes
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, University Park, UK.
| | | | | | | | | | | | | |
Collapse
|
49
|
Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG. Investigating the metabolic changes due to visual stimulation using functional proton magnetic resonance spectroscopy at 7 T. J Cereb Blood Flow Metab 2012; 32:1484-95. [PMID: 22434070 PMCID: PMC3421086 DOI: 10.1038/jcbfm.2012.33] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Proton magnetic resonance spectroscopy ((1)H-MRS) has been used to demonstrate metabolic changes in the visual cortex on visual stimulation. Small (2% to 11%) but significant stimulation induced increases in lactate, glutamate, and glutathione were observed along with decreases in aspartate, glutamine, and glycine, using (1)H-MRS at 7 T during single and repeated visual stimulation. In addition, decreases in glucose and increases in γ-aminobutyric acid (GABA) were seen but did not reach significance. Changes in glutamate and aspartate are indicative of increased activity of the malate-aspartate shuttle, which taken together with the opposite changes in glucose and lactate, reflect the expected increase in brain energy metabolism. These results are in agreement with those of Mangia et al. In addition, increases in glutamate and GABA coupled with the decrease in glutamine can be interpreted in terms of increased activity of the neurotransmitter cycles. An entirely new observation is the increase of glutathione during prolonged visual stimuli. The similarity of its time course to that of glutamate suggests that it may be a response to the increased release of glutamate or to the increased production of reactive oxygen species. Together, these observations constitute the most detailed analysis to date of functional changes in human brain metabolites.
Collapse
Affiliation(s)
- Yan Lin
- Sir Peter Mansfield Magnetic Resonance Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | | | | | | | | |
Collapse
|
50
|
Luckhoo H, Hale JR, Stokes MG, Nobre AC, Morris PG, Brookes MJ, Woolrich MW. Inferring task-related networks using independent component analysis in magnetoencephalography. Neuroimage 2012; 62:530-41. [PMID: 22569064 PMCID: PMC3387383 DOI: 10.1016/j.neuroimage.2012.04.046] [Citation(s) in RCA: 102] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 04/18/2012] [Accepted: 04/23/2012] [Indexed: 12/01/2022] Open
Abstract
A novel framework for analysing task-positive data in magnetoencephalography (MEG) is presented that can identify task-related networks. Techniques that combine beamforming, the Hilbert transform and temporal independent component analysis (ICA) have recently been applied to resting-state MEG data and have been shown to extract resting-state networks similar to those found in fMRI. Here we extend this approach in two ways. First, we systematically investigate optimisation of time-frequency windows for connectivity measurement. This is achieved by estimating the distribution of functional connectivity scores between nodes of known resting-state networks and contrasting it with a distribution of artefactual scores that are entirely due to spatial leakage caused by the inverse problem. We find that functional connectivity, both in the resting-state and during a cognitive task, is best estimated via correlations in the oscillatory envelope in the 8–20 Hz frequency range, temporally down-sampled with windows of 1–4 s. Second, we combine ICA with the general linear model (GLM) to incorporate knowledge of task structure into our connectivity analysis. The combination of ICA with the GLM helps overcome problems of these techniques when used independently: namely, the interpretation and separation of interesting independent components from those that represent noise in ICA and the correction for multiple comparisons when applying the GLM. We demonstrate the approach on a 2-back working memory task and show that this novel analysis framework is able to elucidate the functional networks involved in the task beyond that which is achieved using the GLM alone. We find evidence of localised task-related activity in the area of the hippocampus, which is difficult to detect reliably using standard methods. Task-positive ICA, coupled with the GLM, has the potential to be a powerful tool in the analysis of MEG data.
Collapse
Affiliation(s)
- H Luckhoo
- Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, UK.
| | | | | | | | | | | | | |
Collapse
|